Table 1. 197 Candidate Genes 

RefSeq Gene Symbol Source Forward Primer Reverse Primer Probe 
NM_001562 IL18 Literature AAAATTTCAACTCTCTCCTGTGAGAA ACACTTCTCTGAAAGAATATGATGT CCTTTAAGGAAATGAATCCTCC 
NM_000032 ALAS2 Array1 AACCTAAAGTCCTCACAAAACAACC GCAACAGAGGGCCCACAT TTTTTCTTGTTCCATCCCAG 
NM_000597 IGFBP2 Array2 AAGCATGGCCTGTACAACCT ACGCTGCCCGTTCAGA CAAACAGTGCAAGATGTC 
NM_016562 TLR7 Array1 ACCAGACCTCTACATTCCATTTTGG CCCCAAGGAGTTTGGAAATTAGGAT CCACATTGGAAACACCATTT 
NM_005195 CEBPD Literature ACCAGACTTTTCAGACAAACCCTTT ATTTCAAATGCTGCTTTATTCTTACA AAAAGACTGAGCATGCTCACTT 
NM_207511 FLJ36268 Array2 ACCCAGACGTCCTGGAGATC GGCAGGACAGCCTCCTT CCGGGTGTCTGCATTGA 
NM_002162 ICAM3 Literature ACCCTGGTCGTGGTGATG AGTAACACCGCCACGAAGAC CCCAGCCTCAATGTC 
NM_001001547 CD36 KnowledgeBased ACCTATTGGTCAAGCCATCAGAAAA GTTTGCCTTCTCATCACCAATGG TCCCAGTCTCATTAAGCC 
NM_004938 DAPK1 Array1 ACCTCAGGCGCATTGCT CAGCACGTCCTGAACTGTTTC CAGGCGAATCAACATC 
NM_001912 CTSL1 KnowledgeBased ACGGATTTGAAAGCACAGAATCAGA CCACCCATGCCCCATTCTT CACCCCAGCTGTTCTT 
CF529682 ZNF331 Array2 ACTACCCCTGTGCGTTGTC CACTTTCAAAGACTTTACATGTACCA TCTCAGGTAGATGTGATTATCCTTAT 
NM_001336 CTSZ Associative ACTGAGTACTGGATTGTCCGGAAT GGTGCTGGTCACGATCCT CTCGCCCCATGGTTCA 
NM_014915 ANKRD26 Array2 AGATGCAGCAGGAGTTGGAAAA AGATTTGACTCATCAGTAGACCCTA CAGCAGCAGCTTCTTT 
NM_014380 NGFRAP1 Array2 AGATTGCCTTTGCACTCAGTGT ATTTTTCCATGCAAATGGGTGAAAC CTGCTGACAGAAACTT 
CD633154 C1orf198 Array2 AGCACCCAGCAATAACTCTAATAATG GACTCCCTCCAAGATTGCCTAATTT CCTGAGATTAAATGTAAAATC 
BC022297 DGKE Array2 AGCCGCGCCTCCAC GCCTCTCCGCTTCCATCTTC CCAAGGACGATACCTCGCG 
NM_003853 IL18RAP Literature AGCCTGTGTTTGCTTGAAAGAGAT TCTTCTGCTTCTCTTAATAATGCTCA TCTTCTGCATACACTCCTCC 
NM_004385 CSPG2 Literature AGGAAATGGAAGATGGGCTATACCT CCTTTGCTGATGAGGAATTTTTAAA CTGCATGAACCCATCTGC 
NM_006433 GNLY Literature AGGACCTCAGGTTGTGTATACCT TCTTCCACAGGACAAGGTGAGA TCTACAGGTCCCCTCTGAGCC 
NM_002957 RXRA Array1 AGGCCTACTGCAAGCACAAGTAC GGCAGGCGGAGCAAGAG CCGGGAAGGTTCGCTA 
NM_002703 PPAT Array1 ATTTAATTGGTGGTGAAGCTACTCG TCAGAGGCAATACCATCTCACCTAT CTGGTGCAAAAGAGGTACAC 
NM_033071 SYNE1 Array1 ATTTGTGCTATGTCCATGGAAAGGA GACTTCAGCCAATCTTCAAAACGT ACGTCTCTTCGATTTTCAG 
NM_002965 S100A9 Array2 CAAAGAGCTGGTGCGAAAAGATC CCTCCATGATGTGTTCTATGACCTT TCCTTCTTGAGAAAATTT 
NM_004114 FGF13 Array1 CAAGCCTGCAGCTCATTTTCTG CGTGAGATCGTGCAGTGATG TTGTACATGGCCACTTTC 
NM_014430 CIDEB Associative CAAGGACTTGGCCCAAAGAAAG AGGCCTTGCAGCAGTGT CTCAGGGAGCTCCTTCGTT 
NM_001767 CD2 KnowledgeBased CACTGCTCGTTTTCTATATCACCAAA GCTACTCTGTGGGCTCTTGTC CAGCTCCTCATCATTTC 
NM_000634 IL8RA Literature CAGCTCCTACTGTTGGACACA CCTCTTCAGTTTCAGCAATGGTTTG CCGGTGCTTCAGTTAGAT 
NM_005211 CSF1R Literature CAGGAGCAGGCCCAAGAG GCTGCTCGGCAGATTGGTA CAGGAGAGAGCGGGACTA 
NM_012072 C1QR1 Array2 CAGGGCCATGGAGAACCA CACCTCACTTTCAGCAGTCTGT CCAGGTGTCGGACTGTAC 
NM_002089 CXCL2 Literature CATCGCCCATGGTTAAGAAAATCAT CCAATAAGCTTCCTCCTTCCTTCTG TTGGATTTGCCATTTTTC 
NM_001747 CAPG Literature CATCTCGCGCATGCAGTAC AAATTGCTTGAAGATGGGACTCTCA CTCCACCTGAGTGTTCG 
NM_001124 ADM Literature CATGAAGGGTGCCTCTCGAA GGCGGTAGCGCTTGACT CCCCGAAGACAGCAGTC 
NM_018211 RAVER2 Array1 CATTGCTTATTCTCCACCTTTTGGT TGAGATATGATGAGCCTCGCTTTTC AAGATGACACCTGTGCATAAT 
NM_000655 SELL Literature CATTTGGCTGGCAAGGAGATTAAAA CCAAGGGCGATTTAATATGGGTCAT ATACTTCTCTTGGATTTCTTG 
NM_000997 RPL37 Array2 CCAAGCGCAAGAGAAAGTATAACTG AGGTGTTGTTCCTTCACGGAATC CATGCCTGAATCTGC 
NM_003520 HIST1H2BN Array2 CCAAGTACACCAGTTCCAAGTGA GTGTGGGCCGAGACTGA CCGCCCACCGCGGAA 
NM_203416 CD163 KnowledgeBased CCACACTGAAAAGGAAAATGGGAAT CTCCATTCAATAGTCCAGGTCTTCA CCCAGTGAGTTCAGCCTT 
NM_033125 SLC22A16 Array1(&Array2) CCACTCAGGAGGGCCATAGTC TCTGTGGACCTCAGCAGCATT AAACAACTGTGGTATGAAGAT 
NM_032489 ACRBP Array2 CCAGCAGTGTCTGATGAGAAACC AGCGCACTGTAAGTCTCATTCTG ATGCGGGACACCTTCCGA 
NM_002985 CCL5 Literature CCAGTGGCAAGTGCTCCAA CACACTTGGCGGTTCTTTCG CCAGCAGTCGTCTTTG 
NM_007268 VSIG4 Array2 CCCAACAAGAGCATGTCTACGAA CTCATGGTTTCTCCAGAGTCGTT CATGTGCCCTGGCTGC 
NM_016823 CRK Array2 CCCAATGCCTACGACAAGACA CCCACTGACCACTCACATTAATCTT CCGACCTCCAAAGCC 
NM_016823 CRK SpliceVariant CCCAATGCCTACGACAAGACA CCCACTGACCACTCACATTAATCTT CCGACCTCCAAAGCC 
NM_005206 CRK SpliceVariant CCCAATGCCTACGACAAGACA CCCACTGACCACTCACATTAATCTT CCGACCTCCAAAGCC 
NM_000594 TNF Literature CCCAGGGACCTCTCTCTAATCA CATGGGCTACAGGCTTGTCA AGGCAGTCAGATCAT 
NM_000519 HBD Array1(&Array2) CCCCAAAGGACTCAAAGAACCT GAGGCCCTGGGCAGATTACT TGGGTCCAAGGGTAGAC 
NM_001911 CTSG Array2 CCCCGAAGGCAGATTTGTGT CGTGGGCCACATTGTTACAC ATCCCCCTTGAAGGCAG 
NM_003268 TLR5 Associative CCCTCTGCCCCTAGAATAAGAACAT GCCATGAGCACCACTCCTA CCCATGATCCTCGTTGTCC 
NM_003268 TLR5 Literature CCCTCTGCCCCTAGAATAAGAACAT GCCATGAGCACCACTCCTA CCCATGATCCTCGTTGTCC 
NM_018301 RBM41 KnowledgeBased CCGAATGATGACTGGACGAATGAG GATGCAATGCTTGCCATGCTAT ATCACCTTTCCCAATAAGGAG 
NM_002185 IL7R Literature CCGATCATAAGAAGACTCTGGAACA GCAGTCCAGGAAACTTTCAGGAT AAGAAACCAAGAAAAAATTT 
NM_002619 PF4 Literature CCGGGCTGCTGTTCCT GCAGGTCCCCATCTTCTTCAG TTCGCCAGCGCTGAAG 
NM_001002265 8-Mar Literature CCGTACTGCTGAGGAGATCAAG CAATTTAGTCCAAAAGGGCCATTCT CAGGCAACAGGAATC 
AK123177 C1orf132 Associative CCTCTGCTCTGTCACTTGCT CCTGTTTGCGCAGTACCC TTTCTCTCGGCGGCCTT 
NM_000639 FASLG Literature CCTGAAAAAAAGGAGCTGAGGAAAG CCAGAGGCATGGACCTTGAG TTGGACTTGCCTGTTAAAT 
NM_181453 GCC2 Array1 CCTGAAGAAAAGGGAAAACTTGCT GATAGGATGCCCATCCAGAAGAAC CTCACCTTGAGCAACCG 
NM_001511 CXCL1 Literature CCTGCATCCCCCATAGTTAAGAAAA CTCCTCCCTTCTGGTCAGTTG CTGAACAGTGACAAATC 
NM_000395 CSF2RB Literature CCTTCACTAGCGGGAGTCC GCTGTCCCCGAATCCTACA AACACCCCCTCCAGCTCA 
NM_003807 TNFSF14 Literature CGAAGGTCTCACGAGGTCAAC CCCGCTGCCGGTCAA CTGGAGTTGGCCCCTGTGAG 
NM_001731 BTG1 Array2 CGACAGCTGCAGACCTTCAG GGCTTTTCTGGGAACCAGTGAT CTGCTGGCAGAACAT 
NM_000619 IFNG Literature CGAGATGACTTCGAAAAGCTGACTA GTTCATGTATTGCTTTGCGTTGGA CAAGTCAGTTACCGAATAAT 
NM_002603 PDE7A Literature CGATCGTCACACTGAATCTATTGC ACCTGGCCCATTCTGTAAATAAAGG ACATCCAGATTGGTTTTATG 
NM_001005339 RGS10 Array2 CGCACCCTCTGATGTTCCA GACTTTAAGAAGCGGCTGTAGCT CCAGGACCAGATCTTT 
NM_005018 PDCD1 Literature CGCACGAGGGACAATAGGA CCCATAGTCCACAGAGAACACA CCAGCCCCTGAAGGAG 
NM_016061 YPEL5 Array2 CGCCACTGGCAGAGCAT AGCATGACCCGATCTTGAACTTC CTTTTTAACAAGGTAGTTAACCTGC 
NM_006194 PAX9 Array1 CGGTCAGGCACCAAATGG CATGCTGGATGCTGACACAAA CCCAGCTGTGGGCAG 
NM_207627 ABCG1 KnowledgeBased CGTACCTACAGTGGATGTCCTACA GATCTTCCCGGTCTAAGCCATAG CCTTCGAACCCATACCTGAC 
NM_021205 RHOU Literature CGTGAGACTCCAACTCTGTGA GAGAGGCCTCAGCTTGTCAAAT CTGCCGGACAGGATGA 
BC017379 HIST1H2AC Array2 CTCACTGCTTGTAGGTAGAAGGAAA GATCCTGGCATCTCTCTGAAATGAG ACTAAGGTTGCAAAAGCT 
NM_145168 HSPC105 Array2 CTCATTACAGGAGGAAGTGGCTATT GGCTGCTGATGTCAAACAGAAT CCAGGCGAAAACCAA 
NM_016633 ERAF Array1 CTGAATCAGCAGGTCTTCAATGA CCTCCACCACAGTCACCATGT CCTCTCGTCTCTGAAGAA 
NM_004364 CEBPA Associative CTGCCCACAAGGCTTGTC ACCTCCCTTCCCGACCA CAGAGGCCCTGGCTCC 
NM_014468 VENTX2 Array2 CTGGCCAGGGAGATGCA TGCGGCGATTCTGAAACCA TCTCAGAGGTCCAGATAAA 
NM_000760 CSF3R Literature CTGGGTGCCCACAATCATG GTGGCGTGCCAAGGC CTGGAAGGCATCCTCCTC 
NM_000760 CSF3R SpliceVariant CTGGGTGCCCACAATCATG GTGGCGTGCCAAGGC CTGGAAGGCATCCTCCTC 
NM_000576 IL1B Literature CTGTCCTGCGTGTTGAAAGA TGAAGACAAATCGCTTTTCCA GCTGGAGAGTGTAGATC 
NM_005902 SMAD3 Literature CTTCCTGGCAGGCTGTAGAC CCCTCATGTGTGCTCTTCCTAAG CTCCTGACTCTAGGCTTGTC 
NM_001629 ALOX5AP KnowledgeBased CTTTGTCGGTTACCTAGGAGAGAGA GGAACAGGAAGAGTATGATGCGTTT ACGCAGAGCACCCCTG 
NM_003246 THBS1 KnowledgeBased GAAATGGTGTTCTTCTCTGACCTGA CAGCATTGGTTTATGATCAGTCTTT ATACGAATGTAGAGATCCC 


Table 1. 197 Candidate Genes 

RefSeq Gene Symbol Source Forward Primer Reverse Primer Probe 
AY358234 AY358234 Array1 GAACAGGCGCCAATGCT CCCAGGAGAGACGGAAACAG ACAGCTACCAGGACCC 
NM_181780 BTLA Associative GAACTCTCTGACACAGCAGGAA GCTTCTGTTTGCTCACTCTTAAGGT TCAACCAGGTTAATTTC 
NM_002964 S100A8 Array2 GAAGAAATTGCTAGAGACCGAGTGT GCACCATCAGTGTTGATATCCAACT CACCCTTTTTCCTGATATACT 
NM_002608 PDGFB Literature GACAAGACGGCACTGAAGGA CAGACGGACGAGGGAAACAATATTA AATAACCCTGCCCACACACT 
NM_003810 TNFSF10 Literature GACCAGAGGAAGAAGCAACACA GGCCCAGAGCCTTTTCATTCT TTGTCTTCTCCAAACTCC 
NM_001150 ANPEP Array1 GACGATTCTCCACCGAGTATGAG TTCCTCGTTGTCCTTCTTGAACT TGCAGCAGCTGGAG 
NM_004577 PSPH Array2 GAGATGGTGCCACAGATATGGAA TGCCTGATCACATTTCCTCCAAA CTCCTGCTGATGCTTTC 
NM_000660 TGFB1 Literature GAGCCTGGACACGCAGTA CCCGGGTTATGCTGGTTGTAC CAGCAAGGTCCTGGCCCT 
NM_000660 TGFB1 Literature GAGCCTGGACACGCAGTA CCCGGGTTATGCTGGTTGTAC CAGCAAGGTCCTGGCCCT 
NM_000140 FECH Array1 GAGCTGAGTCTCTTAATGGAAATCC GGATGTGTGAATGCACCAAGTC CAGGGCCTTAGAGAACA 
NM_000119 EPB42 Array1(&Array2) GAGGAGCTACAGATTCCGTTCAG TGAACTGGAACTTGGCACACA TGGCCTGAAAACAC 
NM_004633 IL1R2 Array1 GAGGATTTGCACATGGATTTTAAA GGAGGAGGCTTCCTTGACTGT TGTTGTCCATAATACCC 
NM_002934 RNASE2 Array2 GATCAGTTCTCACAGGAGCTACAG CAGACAAATTTGGGAAGTGAACAGT ACTGGGAAACATGGTTCCAA 
NM_001007225 p62 Array1 GATCGTCAGAATTATCGGGCACTT CTGCTTCACCTGTTGTACAATTTCC CTTTGCTAGCCAGACTGC 
NM_001005743 NUMB Associative GATGCTGCTAACAAGGAAATTGCA TGACCGGCCTGGAAGAGA TCGGTCCCCGAACATG 
NM_020682 AS3MT Array1 GCAAGAGTGATCTGCATGTTTTTT TGGCTCATTTGTTGTTTCTTATGG ACCTGCTTTTCCC 
NM_152939 EMR3 Associative GCAAGATGGGTCCTGACTCA AGTTTTAATATTTTCTCTTCACTTGT ATCCCCCTCACTGGGTTT 
NM_000419 ITGA2B Literature GCACGCATGGTTCAACGT CCCGGAGCAGCTGTGT CCACACCTGAGCTTCC 
NM_021083 XK Array1 GCAGCAGGACGTCACTGT ACACAATGGACAACAGGGATATGG TCATGAGGAGACTTCTTCC 
NM_016332 SEPX1 Array2 GCAGCTCGCTGAAGTTTGTC AACGTGTGGCCTCAGTGT CTAAAGGCAAAGAAACTTC 
AJ243670 UBAP2L Array2 GCATTCTCAGATCCTTCACCATCAC GCTGGTCATCGACGAAATTGAG ATGTCCTGGCCATCCTG 
NM_004001 FCGR2B Literature GCCAATCCCACTAATCCTGATGAG GGTGCATGAGAAGTGAATAGGTGA CTCAGCCCCAACTTT 
NM_021642 FCGR2A KnowledgeBased GCCAATTCCACTGATCCTGTGAA CGTCAGCTGTTTCATAGTCATTGTT TCCAGGTGGCTCAAATT 
NM_003005 SELP Literature GCCACCTAGGAACATATGGAGTTTT CAGAGCTAATCTAAGGTAATTCCAT CCGAGTCCTTAAGGTTTC 
NM_001069 TUBB2 Array2 GCCAGATCTTCAGACCAGACAA GCCCTTGGCCCAGTTATTCC CACTCTGGCCGAACACG 
NM_014731 ProSAPiP1 Array2 GCCCCGGATAGAGGAAACTAAGT GCTGCTTCAGGAGGGAGATC CTGGCACACCTCCC 
NM_001765 CD1C Array1 GCCCTTGGTGATTCTAATAGTCCTT GTTGCTGGGTTCTTAACACAATGG CCTGATATGAGCAGTGCTTC 
NM_003612 SEMA7A Literature GCCGAGCCACACAAGGA GGGCCAGGGAAACCTTCTG AACCAGACAAGGCCCC 
NM_000591 CD14 Literature GCCGGCCGAAGAGTTCA CTCTGGAAGTGCTTTAGCTTCTTTC AAGTGTGAAGCCTGAAGCC 
AF161365 AF161365 Array2 GCCTTGGAACACACCTTCGT CAGGACACACTTCCGATGGATTTA CCCCAGGAGTTGCTG 
NM_000698 ALOX5 Literature GCGCTGAGCCAGTTCCA TCACAGGCTTCTCGATAAAATGCT CCCAGGAACAGCTCGTTTT 
NM_003243 TGFBR3 Literature GCGTTTGCAGCCTTTGTGAT GGGACTTGCTGCCTTCCT CTCCCCTGTGTGAGAATA 
NM_000616 CD4 Literature GCTAGGCATCTTCTTCTGTGTCA CTCACTGAGGAGTCTCTTGATCTGA CTGCTTGGCGCCTTC 
NM_023080 FLJ20989 Array2 GCTCAGATGGAAGCCGAATG GGCTCCATCTACAGGTTGCA TCAGAGCTGCTGCTTATT 
NM_175854 PAN3 Array1 GCTCCCTGGATTGACCTCAGT CTTCTCATCTCTGGAAATCAGGCTT CACCAGCATCTAGCTTGTT 
NM_002923 RGS2 Literature GCTGTCCTCAAAAGCAAGGAAAATA GGGCAATCAGAGTTTTGGTTTGAAA AAGCTCCAAAAGAGATAAACA 
NM_000885 ITGA4 Literature GCTTGCTACTTGGACTTATTGTACTT CTGTCTCTTCTGTTTTCTTCTTGTAG CCAGCCTTCCACATAAC 
NM_000130 F5 Literature GGAAACCATACAGGCTGAAATCCT CACGGATAAACCTGGAAATGATTGG ATGGTGGACAAGATTTTTGA 
NM_000602 SERPINE1 KnowledgeBased GGACAGACCCTTCCTCTTTGTG CCATCACTTGGCCCATGAAAAG CCCCACAGGAACAGTC 
NM_004345 CAMP Array1 GGACAGTGACCCTCAACCA CCCAGCAGGGCAAATCTCTT CATCAGTTGTGATAAGGATAAC 
NM_001671 ASGR1 Associative GGACGGGACGGACTACGA AGTCGTCCGGCTGCTC ACGGGCTTCAAGAACT 
NM_002389 CD46 Associative GGAGAGATGAGAGAAAGGTTTGCTT CTGGAGTGGTTGATTTAGTCTGGTA CACCATCTGCTTTCCTTTTA 
NM_000572 IL10 Literature GGAGCAGGTGAAGAATGCCTTTA AGATGTCAAACTCACTCATGGCTTT CCTTTCTCTTGGAGCTTAT 
NM_001557 IL8RB Literature GGAGGTGTCCTACAGGTGAAAAG TGTCACTCTCCATGTTAAAATCTTCC CCCAGCGACCCAGTCAG 
NM_002115 HK3 Literature GGATGGAACGCTCTACAAGCT CCAGCTCCCGCACTGT CCCGCGCTTCTCCA 
NM_001066 TNFRSF1B Literature GGCGTGGAGGCCAGT CACGATGCAGGTGACATTGAC AGCTCAGATTCTTCCCCTGGTGG 
NM_012425 RSU1 Array2 GGCGTGTCCCATGTTTTTGAGTATA GGGTTGGCCTGCATGTG TCTGCCGTAGAGGTATTT 
NM_012252 TFEC Array2 GGCTAACAGGCGACTTCTACTTC GTTGGCAGACCATGAGTACGA ATTCAGGAACTAGAAATTC 
NM_001337 CX3CR1 KnowledgeBased GGCTGACTGGCAGATCCA TTTCTGTCACTGATTCAGGGAACTG ACGCCAGGCCTTCAC 
NM_003236 TGFA Array1 GGCTGTCCTTATCATCACATGTGT CCGGCACCACTCACAGT CTGGCAGCAGTGTATCA 
NM_005143 HP Array2 GGCTGTTGGAGATAAACTTCCTGAA CTGGGTTTGCCGGATTCTTG CTTCCCACATACTGCTTCAC 
NM_000201 ICAM1 Literature GGGACCATAGGCTCACAACAC GGGCAATGTTGCGAGACC CTGGCAAATTTGATTTTT 
NM_002562 P2RX7 Array2 GGGAGAAGTCTGCAAGATGTCAAG AGCCTGGACAAATCTGTGAAGT CAGGTCTTGGGACTTCT 
NM_152592 C14orf49 Array1 GGGAGCCGACTGGATTCC GTGGGAGCGCCACACA CCGCCGAGTCTTTT 
NM_003527 HIST1H2BO Array2 GGGAGCTGGCCAAGCA TCTGAAAAGAGCCTTTGGATTGCT TTGGAGCTGGTGTACTTG 
NM_001136 AGER KnowledgeBased GGGTCATCTTGTGGCAAAGG CTCCTCTTCCTCCTGGTTTTCTG CCTTCCTCTCCTCTCCTCG 
NM_002631 PGD Array2 GGTACAGACATGAGATGCTTCCA GGTGTGAGCCCCGAAGTAATC CCGCTGAGCCTGGATG 
NM_001771 CD22 Array1 GGTCACTTATTCAGCATTGCACAA TCTGGAAAATCTGGAATGACGTTCT ATAGTCGCCCACTTGGC 
NM_003516 HIST2H2AA Literature GGTCGTGGCAAGCAAGGA GCCCTACCGGGAACTGAAG CCAAGGCCAAGTCGCGCT 
NM_080912 ASGR2 Array2 GGTGGATGGCACAGACTATAGG GTGCCCGTGCCAATTATCTG CAGCCCAGTTCTTGTAGTTG 
NM_033655 CNTNAP3 Array2 GGTTAATGCAGACAGAAGAGACTCT TGGCAGTGATGCAAAGCAAAATAAA TCGGAGGTGTGATAGCAG 
NM_025260 C6orf25 Literature GTAAAGGAGGAAGAGCCCAAGATTC TGAGGGCTAGATGGTCCAGATC AACCGAGCCTGCTCTAT 
NM_000074 CD40L Literature GTCATAAGTGAGGCCAGCAGTAAAA GTTGTTGCTCATGGTGTAGTATCCT CACTGTAACACAGATGTTG 
NM_015397 WDR40A Literature GTCCAAGCCCAGACTAGCA CAGTGGGTGTAAACAGCATTGG AAAGGCTGGCTGAATCA 
NM_021209 NLRC4 Associative GTCCCACAACTCGTCAAGCT GCTGGAAGTTTTTCAGAGGGTTCTT AAAATGCACCTAAAATTC 
NM_001398 ECH1 Array1 GTCTGCAGCATGCTCATGTTC TGTATTCCCGCGACCATTCG CAGGACGCCACGTAGTT 
NM_003112 SP4 KnowledgeBased GTGATGAGCTCCAGAGACATAGAAG AGAACATTCCGGGCATTCAAATCT AACCCATACAGGTGAAAAG 
NM_004049 BCL2A1 Literature GTGTCATAACTCAGTCAAGCTCAGT TGGTGGAGAGCAAAGTCTTGAG ATTGCCTCAACAGCTTCA 
NM_004612 TGFBR1 Literature GTTAAGGCCAAATATCCCAAACAGA CCATTGGCATACCAACATTCTCTCA CAGAGCTGTGAAGCCTT 
NM_004512 IL11RA Literature GTTCTTGGCCTCAGTGATTCCA GCCCTCCTGGGTCCTCTA CAGGTTTGGAGCTCCTGGAC 
NM_001461 FM05 Associative TCACAGAGTGAAATGATGGCAGAAA TCTATGTAGTCTCCCTGAATGGTAT CATACCTTTTGTCAATTTC 
NM_006895 HNMT Array2 TCCATAGTCTCTTAGGTACCAATGCT GGGAAAGCGTGATCCGTACTT CCACTGCTTCCTGACACAA 
NM_004441 EPHB1 Array2 TCCTCACTGCTGGCTTCAC GCCAAGGTGATGCCTATTCTCA CAGATGACATCAGAAGACC 
NM_003242 TGFBR2 Literature TCGAGGGCGACCAGAAATTC CAGTCAACGTCTCACACACCAT CCACCAGGGCATCCAG 
NM_001482 GATM Array1 TCTCGGCTTGGACGAACCT TGCCTGGGTGCTCTGGAA TGGGTGCAGCGAAC 
NM_005621 S100A12 Array2 TCTCTAAGGGTGAGCTGAAGCA CCAGGCCTTGGAATATTTCATCAAT CAAACACCATCAAGAATAT 
BC030533 TRBC1 KnowledgeBased TCTGCCACCATCCTCTATGAGAT CCAGGGCTGCCTTCAGAAAT CCATGGTCAAGAGAAAG 
NM_198833 SERPINB8 Array2 TCTGCTTCCCGATGACAACAC TGTCCAGGCTTTGAATTTCTCATATG CTCGCCGTGGTGGAAA 
NM_005761 PLXNC1 Associative TGAAGAAGTGGCCTTGACAGAAATT CAGCCCTCGTTCTCTTTCTAGTTTA TCGTAAAATATTTTGATGAGATTCT 


Table 1. 197 Candidate Genes 

RefSeq Gene Symbol Source Forward Primer Reverse Primer Probe 
NM_013314 BLNK Array1 TGAAGAGGCATTGCACAGATCAAA TGGCCAGAGCTTTTCCGAAT CAAGGATGGATCATTTCTT 
NM_030759 NRBF2 Associative TGAAGCCATGAAGCTGACACA GCTATCCCTTTGCAATTCCAGTGA TCAGAGCAGGCTCATCTT 
NM_003942 RPS6KA4 Array2 TGCGCTCGGGTCTCAAC CTCCACGCTCTTCAGGAAGAAG CCTTCATGGCATTCAAC 
NM_014895 C6orf84 Array2 TGGAAATGAGACATGCACAAAGAGA GCTCAGTTTCTACTACTTGGTGTGT CAGGAACTTCAACAGATAAT 
NM_001770 CD19 KnowledgeBased TGGAGCACCAGGTGATCCT TCGAGGTCTTCAGATTTCAGAGTCA CCAGGCTGGCCACCTG 
ENST00000275874 RAB19B Array1 TGGAGCTGCAAATGTGGTCAT GGACGTGCCGCTTTTCC ATGCTGATTGGAAATAAAT 
NM_016221 DCTN4 KnowledgeBased TGGCAGAACCTCAAGACTTTCAG ACCCACTTTGTTGGCCTTTCT ACGATCCTGACATTATAGCCTT 
NM_006137 CD7 KnowledgeBased TGGCGGTGATCTCCTTCCT CCGCCACGAGCACAGT CTTTATCTGTGTCCTCGCCAGCA 
NM_024837 ATP8B4 Array1 TGGTGGCATTCAGATTTTTGAA CCGGCGGATCTGATCACT TGGATTTATACCCAACCCT 
AK002041 FLJ11179 Array1 TGTGTTGGGTGCAAGTATAATTTAGT GCACACCTGACATGAAAGAGTAAGA CCTGACTTCACCACTATGC 
NM_004283 RAB3D Array2 TGTTGTGCCTGCTGAGGAT GGCACTGGCTTCAAAGAACTC CCGACGACCTTGGTTTC 
NM_172004 DCAL1 Array2 TTAGAACTCGCGTTTCCACTTCA GGCAGGACATGATTTATGGACAGTA AAGTTGAAAGAAACAGATCTC 
NM_001655 ARCN1 Array2 TTCCCTGTTCAAGTTTCCTTTGTCT GAAAGTGGTCTCTGTGGAAAACCT CATACAGGTTACCAAAGTGAC 
NM_004568 SERPINB6 Array2 TTGGCAAGGAACTGAATATGATCAT CCTCGTCCATTCTACGAACTTCTC CTCCACCGTTCTCAAGTCA 
NG_000006 HBM Array1(&Array2) TTTCCGCTGCTAATCCAGTGT TGCATTTGCACGGTGAACTC CGTGCTGGCCTCC 
NM_014009 FOXP3 KnowledgeBased TTTGCCTTCTTCAGAAACCATCCT ACTTGTGCAGACTCAGGTTGTG CCACCTGGAAGAACGC 
NM_002922 RGS1 Literature TTTTGCCCTGTAAAGCAGAAGAGAT GATTCTCGAGTGCGGAAGTCAATA ATGCTGCTAAACAAATCAA 
NM_172215 CAMKK2 Array1 AAAACCAACCAGGGAATGTGAGT GTTACTTTGCAACAGGCAGGAA CTCAAGACCTAGAAAATAAG 
NM_138806 CD200R Array1 TGAAAGTCAATGGCTGCAGAAAATA CTTCTCTGTGTAGCTGGCATAGG CATTTCATCCTCCTCAACAAC 
NM_144682 FLJ31952 Array1 TGGAACACAAAGCTGATCTACAACA GGGACTCTGGAGTACATTCCAAATG CTGGTGGAACTGGAAATA 
NM_153021 PLB1 Array1 GCCGAGCCAAACTCAAGTG TCCGCAGGGTGTAGAGGTAA CTCTCCTGAGAGCCC 
NM_182898 CREB5 Array2 ACTGCAGGAAGCAACACGTT GCCTCTCCTGCTCCAAATTCAT CTTGGATTCCTCATAAATCA 
NM_172247 CSF2RA Array2 GCTCCTGGAGTGAAGCCATT TGGAACTGGCGGGAACAG CCTAAGGAACCAAATTC 
NM_147148 GSTM4 Array2 CCTTGACCTCCACCGTATATTTGAG CCCAGTCAAGTTGATGCAGAAAATT CCACAGGAAACCTCAAAGC 
NM_178507 NS5ATP13TP2 Array2 CAGGAGGATGTCCGGTTCTG GCAGAGCCTCGAACACAGA CTGTCCACACCTTGCTCC 
NM_130782 RGS18 Array2 AAATTCACCTTAAAGCAAAAGCAATA GTTGAGTGATGCTGTTTGTAATGAC CCCAAAAGAGTTAACCTTG 
NM_006290 TNFAIP3 Array2 AGAGATTTCATGAGGCCAAAAGGA GGCCTTGAGGTGCTTTGTG TCGATCTCAGTTGCTCTTC 
NM_170662 CBLB Literature TCACAGGACTATGATCAGCTTCCTT GCGCGGTCGTGGTTTAG CTGTGAACCATCTGAACATG 
NM_171827 CD8A Literature CCGAAGACGTGTTTGCAAATGT CTGGGCTTGTCTCCCGATTT CCCCGGCCTGTGGTC 
NM_173841 IL1RN Literature AGCTCAGTTGAGTTAGAGTCTGGAA CCTCCTCCACCTCCTTCTTCATA CCATGGCTTTAGCTGACTTG 
NM_005084 PLA2G7 
Literature GATCTTAGCAACAAAGCTTCATTAGC TCAATCAAGCAGTCCCACTGATC CATTTAGGACTTCATAAAGATTTT 
NM_001065 TNFRSF1A Literature CGCCCACAAGCCACAGA TCCACCACGGCGTACAG CCTAGACACTGATGACCC 
NM_080913 ASGR2 SpliceVariant CCCCAGTTCTCCTGGCTTTAAC GGGCTGAGGTTGCTCTGA CTTTCACAGCCCCAGCCC 
NM_001011666 CREB5 SpliceVariant GGGAATTCAGCCTCAGTGATGTC GTTGTGGAGATGTAGCAGAGAAGA CTGGGACAGGCCTCATG 
NM_172247 CSF2RA SpliceVariant GCTCCTGGAGTGAAGCCATT TGGAACTGGCGGGAACAG CCTAAGGAACCAAATTC 
NM_006140 CSF2RA SpliceVariant GAACCCTGTACGTGCTTCCTT CATGGTGCTGGTCAGAGAGAA CCTGTCGCTCTTCCC 
NM_156039 CSF3R SpliceVariant CAGCCACTGTCCCTGTCT GCAGCCTGGGCTCCTG CAGCTCCTCCATGATTG 
NM_172313 CSF3R SpliceVariant GGAGCATGATCTGGTCCTTAAAGT GGACCCAAGAGCAGTTTCCA CCCAGCCTGATCGCT 
NM_173842 IL1RN SpliceVariant ACTCTGGGCCCGCAATG GGCCTCTGCAGATTTCCATTCT ACTGCAGCAAGGCAG 


Table 2. Clinical characteristics Cohort 1 


Unstable (N=45) Stable (N=29) Controls (N=24) 
Age at visit Range 41-82, 
mean 63.4 
Range 48-91, 
mean 66.5 
Range 42-76, 
mean 60 
Males 32 (71%) 24 (83%) 7 (29%) 
History 
Diabetes 13 (29%) 10 (34%) 0 (0%) 
Smoking 15 (33%) 7 (24%) 7 (29%) 
Elevated Cholesterol 24 (53%) 15 (52%) 9 (38%) 
Hypertension 34 (76%) 23 (79%) 14 (58%) 
Homocysteine 2 (4%) 0 (0%) 0 (0%) 
CHF 0 (0%) 0 (0%) 0 (0%) 
Family Hx Premature CAD 3 (7%) 9 (31%) 4 (17%) 
Acute Coronary 28 (62%) 0 (0%) 0 (0%) 
MI 8 (18%) 0 (0%) 0 (0%) 
Unstable Angina 22 (49%) 0 (0%) 0 (0%) 
Inflammatory Disease 0 (0%) 0 (0%) 0 (0%) 
CABG 6 (13%) 0 (0%) 0 (0%) 
Other 5 (11%) 4 (14%) 0 (0%) 
Previous Angiography 13 (29%) 0 (0%) 0 (0%) 
Indication for Current Angiography 
Stable Angina 0 (0%) 29 (100%) 14 (58%) 
Unstable Angina 45 (100%) 0 (0%) 0 (0%) 
MI < 1d 1 (2%) 0 (0%) 0 (0%) 
MI > 1d, <2 wks 0 (0%) 0 (0%) 0 (0%) 
MI > 2 wks 0 (0%) 0 (0%) 0 (0%) 
Positive Stress Test 2 (4%) 2 (7%) 3 (13%) 
Other (see comments) 3 (7%) 0 (0%) 9 (38%) 
Lab Studies 
WBC Level Range 4.8-10, 
mean 7.3 
Range 5.15-9.23, 
mean 6.9 
Range 3.33-9.28, 
mean 6.65 
LDL Level N=10 
Range 88-247, 
mean 158 
N=12 
Range 67-190, 
mean 146 
N=10 
Range 110-215, 
mean 165 
Medication 
Antithrombotics 27 (60%) 12 (41%) 6 (25%) 
Anti-anginal/vasodilator agent 14 (31%) 3 (10%) 2 (8%) 
Statins 16 (36%) 9 (31%) 0 (0%) 
ACE Inhibitors 13 (29%) 7 (24%) 5 (21%) 
Previous Native 


Table 2. Clinical characteristics Cohort 1 


Unstable (N=45) Stable (N=29) Controls (N=24) 
Stenosis 13 (29%) 0 (0%) 0 (0%) 
Thombus 1 (3.4%) 0 (0%) 0 (0%) 
PTCA 5 (11%) 0 (0%) 0 (0%) 
Re-stenosis 0 (0%) 0 (0%) 0 (0%) 
Stent 5 (11%) 0 (0%) 0 (0%) 
Previous Graft 
Stenosis 1 (3.4%) 0 (0%) 0 (0%) 
Thombus 0 (0%) 0 (0%) 0 (0%) 
PTCA 1 (3.4%) 0 (0%) 0 (0%) 
Re-stenosis 0 (0%) 0 (0%) 0 (0%) 
Stent 1 (3.4%) 0 (0%) 0 (0%) 


Table 3. 162 Candidate genes identified in first microarray analysis 


NCBI ID Agilent ID Title Line Custom Whole Genome 
NM_031460 A_24_P112032 Homo sapiens potassium channel, subfamily 
K, member 17 (KCNK17), mRNA 
Unstable vs Stable 
NM_031305 A_23_P110151 Homo sapiens Rho GTPase activating protein 
24 (ARHGAP24), mRNA 
Unstable vs Stable 
NM_006194 A_32_P70818 Human PAX-9 mRNA, partial cds Unstable vs Clean 
NG_002775 A_24_P610945 Homo sapiens keratin pseudogene 
(LOC147228) on chromosome 17 
Unstable vs Clean 
NM_024837 A_23_P163216 Homo sapiens mRNA for KIAA1939 protein Unstable vs Clean 
NG_000006 A_23_P15055 Homo sapiens alpha globin region (HBA@) 
on chromosome 16 
Unstable vs Clean 
NM_000119 A_23_P140675 Homo sapiens erythrocyte membrane protein 
band 4.2 (EPB42), mRNA 
Unstable vs Clean 
NM_016633 A_23_P135486 Homo sapiens erythroid associated factor 
(ERAF), mRNA 
1.5 Unstable v 
Clean 
Unstable vs Clean 
NM_006121 A_23_P128235 Homo sapiens keratin 1 (epidermolytic 
hyperkeratosis) (KRT1), mRNA 
Unstable vs Clean 
NM_020682 A_23_P12643 Homo sapiens Cyt19 protein (CYT19), 
mRNA 
Unstable vs Clean 
NM_144711 A_23_P165408 Homo sapiens kelch-like 23 (Drosophila) 
(KLHL23), mRNA 
Stenotic vs Clean, 
Unstable vs Clean 
NM_001398 A_24_P617578 Homo sapiens enoyl Coenzyme A hydratase 
1, peroxisomal (ECH1), mRNA 
Unstable vs Stable 
NM_002703 A_23_P80940 Homo sapiens phosphoribosyl pyrophosphate 
amidotransferase (PPAT), mRNA 
[NM_002703] 
1.3 Unstable v 
Stable 
Unstable vs Stable 
NM_016562 A_23_P62437 Homo sapiens toll-like receptor 7 (TLR7), 
mRNA 
Unstable vs Clean 
NM_020894 A_32_P319880 Homo sapiens mRNA for KIAA1530 protein, 
partial cds 
Stenotic vs Clean, 
Stable vs Clean, 
Unstable vs Clean 
NM_015011 A_32_P202246 Homo sapiens mRNA for KIAA0865 protein, 
partial cds (MYR8) 
Stable vs Clean 
NM_002337 A_32_P106883 Homo sapiens low density lipoprotein 
receptor-related protein associated protein 1 
(LRPAP1), mRNA 
Stable vs Clean 
NM_017709 A_24_P935893 Homo sapiens family with sequence similarity 
46, member C (FAM46C), mRNA 
Unstable vs Stable 
NM_001150 A_23_P88626 Homo sapiens alanyl (membrane) 
aminopeptidase (aminopeptidase N, 
aminopeptidase M, microsomal 
aminopeptidase, CD13, p150) (ANPEP), 
mRNA 
Stable vs Clean 
NM_000519 A_23_P87346 Homo sapiens hemoglobin, delta (HBD), 
mRNA 
1.5 Unstable v 
Clean 
Unstable vs Clean 
NM_004633 A_23_P79398 Homo sapiens interleukin 1 receptor, type II 
(IL1R2), transcript variant 1, mRNA 
Unstable vs Stable 
NM_001724 A_23_P70843 Homo sapiens 2,3-bisphosphoglycerate 
mutase (BPGM), transcript variant 1, mRNA 
[NM_001724] 
1.3 Unstable v 
Stable 
Unstable vs Stable 
NM_002957 A_23_P423197 Homo sapiens retinoid X receptor, alpha 
(RXRA), mRNA 
Stable vs Clean 
NM_033125 A_23_P42004 Homo sapiens solute carrier family 22 
(organic cation transporter), member 16 
(SLC22A16), mRNA [NM_033125] 
1.3 Unstable v 
Stable 
Unstable vs Stable 


Table 3. 162 Candidate genes identified in first microarray analysis 


NCBI ID Agilent ID Title Line Custom Whole Genome 
NM_025168 A_23_P377350 Homo sapiens leucine rich repeat containing 1 
(LRRC1), mRNA 
Unstable vs Stable 
NM_004690 A_23_P366230 Homo sapiens LATS, large tumor suppressor, 
homolog 1 (Drosophila) (LATS1), mRNA 
Stable vs Clean 
NM_005217 A_23_P31816 Homo sapiens defensin, alpha 3, neutrophil-
specific (DEFA3), mRNA [NM_005217] 
1.3 Stable v Clean, 
1.5 Unstable v 
Clean 
Whole Genome 
All 
NM_000032 A_23_P256061 Homo sapiens aminolevulinate, delta-, 
synthase 2 (sideroblastic/hypochromic 
anemia) (ALAS2), nuclear gene encoding 
mitochondrial protein, mRNA [NM_000032] 
1.3 Unstable v 
Stable 
Unstable vs 
Stable, Unstable 
vs Clean 
NM_000677 A_23_P137931 Homo sapiens adenosine A3 receptor 
(ADORA3), mRNA 
Unstable vs 
Stable, Unstable 
vs Clean 
NM_001482 A_23_P129064 Homo sapiens glycine amidinotransferase (Larginine:
glycine amidinotransferase) 
(GATM), mRNA 
Unstable vs Stable 
NM_152311 A_23_P127107 Homo sapiens transmembrane protein 12 
(TMEM12), mRNA 
Stable vs Clean 
NM_004345 A_23_P253791 Homo sapiens cathelicidin antimicrobial 
peptide (CAMP), mRNA 
Stable vs Clean 
NM_001004303 A_32_P182299 Homo sapiens chromosome 1 open reading 
frame 168 (C1orf168), mRNA 
Stable vs Clean 
NM_001007225 A_23_P95672 Homo sapiens hepatocellular carcinoma 
autoantigen (p62) mRNA, complete cds 
Stenotic vs Clean, 
Unstable vs Clean 
NM_000236 A_23_P88561 Homo sapiens lipase, hepatic (LIPC), mRNA 
[NM_000236] 
1.3 Stable v Clean 
NM_016447 A_23_P71053 Homo sapiens membrane protein, 
palmitoylated 6 (MAGUK p55 subfamily 
member 6) (MPP6), mRNA [NM_016447] 
1.3 Unstable v 
Stable 
NM_000559 A_23_P64538 Homo sapiens hemoglobin, gamma A 
(HBG1), mRNA [NM_000559] 
1.5 Unstable v 
Clean 
NM_032556 A_23_P501713 Homo sapiens interleukin 1 family, member 
10 (theta) (IL1F10), transcript variant 1, 
mRNA [NM_032556] 
1.3 Stenotic v 
Clean, 1.3 Stable v 
Clean 
NM_003153 A_23_P47879 Homo sapiens signal transducer and activator 
of transcription 6, interleukin-4 induced 
(STAT6), mRNA [NM_003153] 
1.3 Stable v Clean 
NM_001937 A_23_P427533 Homo sapiens dermatopontin (DPT), mRNA 
[NM_001937] 
1.3 Unstable v 
Stable 
NM_172215 A_23_P408830 Homo sapiens calcium/calmodulin-dependent 
protein kinase kinase 2, beta (CAMKK2), 
transcript variant 6, mRNA [NM_172215] 
1.5 Unstable v 
Clean 
NM_020211 A_23_P372305 Homo sapiens RGM domain family, member 
A (RGMA), mRNA [NM_020211] 
1.3 Stable v Clean 
NM_004235 A_23_P32233 Homo sapiens Kruppel-like factor 4 (gut) 
(KLF4), mRNA [NM_004235] 
1.3 Stable v Clean 
NM_001738 A_23_P168916 Homo sapiens carbonic anhydrase I (CA1), 
mRNA [NM_001738] 
1.5 Unstable v 
Clean 
NM_004245 A_23_P129291 Homo sapiens transglutaminase 5 (TGM5), 
transcript variant 2, mRNA [NM_004245] 
1.3 Stable v Clean 
NM_001765 A_23_P51767 Homo sapiens CD1C antigen, c polypeptide 
(CD1C), mRNA 
Unstable vs Stable 
NM_005992 A_23_P40527 Homo sapiens T-box 1 (TBX1), transcript Unstable vs Stable 


Table 3. 162 Candidate genes identified in first microarray analysis 


NCBI ID Agilent ID Title Line Custom Whole Genome 
variant B, mRNA 
NM_000140 lit.v.02692_2332 ferrochelatase (protoporphyria) 1.3 Unstable v 
Clean (custom 
clone) 
NM_021977 A_32_P14178 Homo sapiens solute carrier family 22 
(extraneuronal monoamine transporter), 
member 3 (SLC22A3), mRNA 
Unstable vs Clean 
NM_005590 A_24_P800009 Homo sapiens MRE11 meiotic recombination 
11 homolog A (S. cerevisiae) (MRE11A), 
transcript variant 2, mRNA 
Unstable vs Clean 
NM_153021 A_24_P379616 Homo sapiens phospholipase B1 (PLB1), 
mRNA 
Unstable vs Clean 
NM_001771 A_24_P254106 CD22 antigen Unstable vs Clean 
NM_003944 A_23_P86021 Homo sapiens selenium binding protein 1 
(SELENBP1), mRNA 
Unstable vs Clean 
NM_015170 A_23_P43164 Homo sapiens sulfatase 1 (SULF1), mRNA Unstable vs Clean 
NM_033071 A_23_P42451 Homo sapiens mRNA for KIAA1756 protein, 
partial cds 
Unstable vs Clean 
NM_138806 A_23_P41217 Homo sapiens cell surface glycoprotein 
receptor CD200 (CD200R), transcript variant 
1, mRNA 
Unstable vs Clean 
NM_003236 A_23_P377291 Homo sapiens transforming growth factor, 
alpha (TGFA), mRNA 
Unstable vs Clean 
NM_018211 A_23_P328323 Homo sapiens mRNA for KIAA1579 protein, 
partial cds 
Unstable vs Clean 
NM_144682 A_23_P301105 Homo sapiens likley ortholog of mouse 
schlafen 10 (FLJ31952), mRNA 
Unstable vs Clean 
NM_004114 A_23_P217319 Homo sapiens fibroblast growth factor 13 
(FGF13), transcript variant 1A, mRNA 
Unstable vs Clean 
NM_000900 A_23_P204286 Homo sapiens matrix Gla protein (MGP), 
mRNA 
Unstable vs Clean 
NM_017640 A_23_P19369 Homo sapiens leucine rich repeat containing 
16 (LRRC16), mRNA 
Unstable vs Clean 
NM_002172 A_23_P157920 Homo sapiens interferon, alpha 14 (IFNA14), 
mRNA 
Unstable vs Clean 
NM_173708 A_24_P182122 Homo sapiens NADH dehydrogenase 1 
(MTND1), mRNA 
Stable vs Clean 
NM_031933 A_23_P58854 Homo sapiens wingless-type MMTV 
integration site family, member 8A 
(WNT8A), transcript variant 1, mRNA 
[NM_031933] 
1.3 Unstable v 
Stable 
BC017869 lit.v.05686_214 Similar to RIKEN cDNA 1110020F21 gene 
[Homo sapiens], mRNA sequence 
1.3 Unstable v 
Clean (custom 
clone) 
AL353944 lit.v.00036_535 Homo sapiens mRNA; cDNA 
DKFZp761J1112 (from clone 
DKFZp761J1112), mRNA sequence 
1.3 Unstable v 
Clean (custom 
clone) 
AK074343 lib.v.00349_1134 nudix (nucleoside diphosphate linked moiety 
X)-type motif 4 pseudogene 2 
1.3 Unstable v 
Clean (custom 
clone) 
D86974 A_32_P28264 Homo sapiens mRNA for KIAA0220 Unstable vs Clean 
AK002041 A_32_P208713 Homo sapiens cDNA FLJ11179 fis, Unstable vs Clean 
NM_175854 A_32_P185398 PABP1-dependent poly A-specific 
ribonuclease 
Unstable vs Clean 


Table 3. 162 Candidate genes identified in first microarray analysis 


NCBI ID Agilent ID Title Line Custom Whole Genome 
NG_002418 A_24_P648880 Homo sapiens Meis1 homolog 3 (mouse) 
pseudogene 2 (MEIS3P2) on chromosome 17 
Unstable vs Clean 
NM_004938 A_24_P602168 death-associated protein kinase 1 Unstable vs Clean 
AK055895 A_24_P566932 Homo sapiens cDNA FLJ31333 fis Unstable vs Clean 
XM_511209 A_24_P475864 PREDICTED: Pan troglodytes similar to 
BTG3 associated nuclear protein isoform a; 
BANP homolog; SMAR1 homolog 
(LOC454360), mRNA 
Unstable vs Clean 
CR618142 A_24_P161233 full-length cDNA clone CS0DI004YB23 of 
Placenta Cot 25-normalized of Homo sapiens 
(human). 
Unstable vs Clean 
AL359062 A_24_P139152 Homo sapiens mRNA full length insert cDNA 
clone EUROIMAGE 1913076. 
Unstable vs Clean 
NG_000007 A_23_P64539 Homo sapiens beta globin region (HBB@) on 
chromosome 11 
Unstable vs Clean 
NM_152592 A_23_P2901 C14orf49 Unstable vs Clean 
AK131421 A_32_P222398 Homo sapiens cDNA FLJ16540 Unstable vs Stable 
NM_013314 A_24_P64344 Homo sapiens B-cell linker (BLNK), mRNA Unstable vs Stable 
NG_001019 A_24_P367432 Homo sapiens immunoglobulin heavy locus 
(IGH@) on chromosome 14 
Unstable vs Stable 
M69012 A_24_P127159 Human guanine nucleotide-binding regulatory 
protein (G-y-2-alpha) mRNA, partial cds 
Unstable vs Stable 
XM_496159 A_24_P101226 PREDICTED: Homo sapiens similar to 
KIAA1501 protein (LOC440371), mRNA 
(IgG heavy - JAW note) 
Unstable vs Stable 
AK125106 A_24_P14776 Homo sapiens cDNA FLJ43116 fis, clone 
CTONG3002127, weakly similar to Mus 
musculus synaptotagmin-like 4 (Sytl4) 
Stenotic vs Clean, 
Unstable vs Clean 
AY358234 A_24_P935902 Homo sapiens clone DNA142975 
EPWW6493 
Stenotic vs Clean, 
Stable vs Clean 
NM_173498 A_23_P25069 Homo sapiens ovostatin 2 (OVOS2), mRNA MI vs Clean, 
Unstable vs Stable 
AK023667 A_23_P7473 Homo sapiens cDNA FLJ13605 fis, clone 
PLACE1010562. [AK023667] 
1.3 Stable v Clean 
AF288741 A_23_P57466 Homo sapiens oxysterol binding protein 2 
(OSBP2) mRNA, complete cds. [AF288741] 
1.5 Unstable v 
Clean 
NM_021083 A_23_P45304 Homo sapiens Kell blood group precursor 
(McLeod phenotype) (XK), mRNA 
[NM_021083] 
1.3 Unstable v 
Stable 
NM_178161 A_23_P428329 Homo sapiens pancreas specific transcription 
factor, 1a (PTF1A), mRNA [NM_178161] 
1.3 Unstable v 
Stable 
ENST00000275874 A_23_P258208 GTP-binding protein RAB19B (Fragment). 
[Source:SPTREMBL;Acc:Q9UL27] 
[ENST00000275874] 
1.3 Unstable v 
Stable 
A_23_P256366 A_23_P256366 Unknown 1.5 Unstable v 
Clean 
NM_181453 A_23_P209373 Homo sapiens GRIP and coiled-coil domain 
containing 2 (GCC2), transcript variant 1, 
mRNA [NM_181453] 
1.3 Unstable v 
Stable 
NM_024921 A_23_P159764 Homo sapiens premature ovarian failure 1B 
(POF1B), mRNA [NM_024921] 
1.3 Unstable v 
Stable 
NM_138983 A_23_P154849 Homo sapiens oligodendrocyte transcription 
factor 1 (OLIG1), mRNA [NM_138983] 
1.3 Unstable v 
Stable 
NM_001836 A_23_P151778 Homo sapiens chymase 1, mast cell (CMA1), 1.3 Unstable v 


Table 3. 162 Candidate genes identified in first microarray analysis 


NCBI ID Agilent ID Title Line Custom Whole Genome 
mRNA [NM_001836] Stable 
NM_006458 A_23_P150619 Homo sapiens tripartite motif-containing 3 
(TRIM3), transcript variant 1, mRNA 
[NM_006458] 
1.3 Unstable v 
Stable 
BC035682 A_23_P15055 Homo sapiens, clone IMAGE:5749846, 
mRNA. [BC035682] 
1.5 Unstable v 
Clean 
A_23_P140454 A_23_P140454 Unknown 1.3 Unstable v 
Stable 
NM_033069 A_23_P134058 Homo sapiens chromosome 6 open reading 
frame 114 (C6orf114), mRNA [NM_033069] 
1.3 Unstable v 
Stable 
NM_022144 A_23_P125588 Homo sapiens tenomodulin protein (TNMD), 
mRNA [NM_022144] 
1.3 Unstable v 
Stable 
NM_002686 A_23_P100642 Homo sapiens phenylethanolamine Nmethyltransferase 
(PNMT), mRNA 
[NM_002686] 
1.5 Unstable v 
Clean 
NM_144621 A_32_P74763 Homo sapiens zinc finger and BTB domain 
containing 8 (ZBTB8), mRNA 
Whole Genome 
All 
NM_002200 A_32_P217500 Homo sapiens interferon regulatory factor 5 
(IRF5), transcript variant 1, mRNA 
Whole Genome 
All 
NM_016184 A_23_P500271 Homo sapiens C-type (calcium dependent, 
carbohydrate-recognition domain) lectin, 
superfamily member 6 (CLECSF6), transcript 
variant 1, mRNA 
Whole Genome 
All 
NM_002609 A_23_P48029 Homo sapiens platelet-derived growth factor 
receptor, beta polypeptide (PDGFRB), mRNA 
Whole Genome 
All 
NM_001400 A_23_P421401 Homo sapiens endothelial differentiation, 
sphingolipid G-protein-coupled receptor, 1 
(EDG1), mRNA 
Whole Genome 
All 
NM_001911 A_23_P404481 Homo sapiens cathepsin G (CTSG), mRNA Whole Genome 
All 
THC1848212 A_23_P140384 Unknown Whole Genome 
All 
NM_033297 A_23_P101434 Homo sapiens NACHT, leucine rich repeat 
and PYD containing 12 (NALP12), mRNA 
Whole Genome 
All 
AK129833 A_32_P72028 Homo sapiens cDNA FLJ26323 fis, clone 
HRT00813, highly similar to Tissue factor 
pathway inhibitor 2 precursor (TFPI-2) 
Stenotic vs Clean 
NM_005468 A_32_P453971 Homo sapiens N-acetylated alpha-linked 
acidic dipeptidase-like 1 (NAALADL1), 
mRNA 
Stenotic vs Clean 
M83772 A_32_P358264 Human flavin-containing monooxygenase 
form II (FMO2) mRNA, complete cds 
Stenotic vs Clean 
NM_014424 A_32_P35165 Homo sapiens heat shock 27kDa protein 
family, member 7 (cardiovascular) (HSPB7), 
mRNA 
Stenotic vs Clean 
AK023112 A_32_P117185 Homo sapiens cDNA FLJ13050 fis, clone 
NT2RP3001432 
Stenotic vs Clean 
AK127795 A_24_P95070 Homo sapiens cDNA FLJ45896 Stenotic vs Clean 
BC036441 A_24_P791862 Homo sapiens hypothetical protein 
LOC149351, mRNA (cDNA clone 
IMAGE:5273076), with apparent retained 
intron 
Stenotic vs Clean 
AL713714 A_24_P756766 Homo sapiens mRNA; cDNA 
DKFZp667C0715 (from clone 
Stenotic vs Clean 


Table 3. 162 Candidate genes identified in first microarray analysis 


NCBI ID Agilent ID Title Line Custom Whole Genome 
DKFZp667C0715) 
A_32_P117185 A_24_P666035 Unknown Stenotic vs Clean 
AW293971 A_24_P523325 Unknown Stenotic vs Clean 
NM_001007530 A_24_P500584 Homo sapiens cDNA FLJ13050 fis, clone 
NT2RP3001432 
Stenotic vs Clean 
BC033366 A_24_P398147 Homo sapiens keratin 1B, mRNA (cDNA 
clone IMAGE:4780346) 
Stenotic vs Clean 
THC1953243 A_24_P31627 Unknown Stenotic vs Clean 
AK025198 A_24_P119783 Homo sapiens cDNA: FLJ21545 fis, clone 
COL06195 
Stenotic vs Clean 
NM_006393 A_23_P96325 Homo sapiens nebulette (NEBL), transcript 
variant 1, mRNA 
Stenotic vs Clean 
NM_004975 A_23_P63736 Homo sapiens potassium voltage-gated 
channel, Shab-related subfamily, member 1 
(KCNB1), mRNA 
Stenotic vs Clean 
AF116692 A_23_P52668 Homo sapiens PRO2207 mRNA, complete 
cds 
Stenotic vs Clean 
AK074719 A_23_P4953 Homo sapiens cDNA FLJ90238 fis, clone 
NT2RM2000632, weakly similar to 
EXCISION REPAIR PROTEIN ERCC-6 
Stenotic vs Clean 
NM_032770 A_23_P155596 Homo sapiens hypothetical protein 
MGC16291 (MGC16291), mRNA 
Stenotic vs Clean 
NM_018215 A_23_P103703 Homo sapiens hypothetical protein FLJ10781 
(FLJ10781), mRNA 
Stenotic vs Clean 
NM_012304 A_32_P171386 F-box and leucine-rich repeat protein 7 Stenotic vs Clean 
AK058031 A_32_P86763 Human flavin-containing monooxygenase 
form II (FMO2) mRNA, complete cds 
MI vs Clean 
A_32_P234294 A_32_P234294 Homo sapiens hypothetical protein 
LOC149351, mRNA (cDNA clone 
IMAGE:5273076), with apparent retained 
intron 
MI vs Clean 
AB067467 A_32_P217401 Homo sapiens cDNA FLJ31996 fis, clone 
NT2RP7009253. 
MI vs Clean 
AK023827 A_32_P212108 Homo sapiens cDNA FLJ90238 fis, clone 
NT2RM2000632, weakly similar to 
EXCISION REPAIR PROTEIN ERCC-6 
MI vs Clean 
NM_016530 A_32_P198791 Homo sapiens cDNA: FLJ21545 fis, clone 
COL06195 
MI vs Clean 
XM_056680 A_32_P158786 PREDICTED: Homo sapiens hypothetical 
protein LOC115749 (LOC115749), mRNA 
MI vs Clean 
AK128413 A_24_P934162 hypothetical protein LOC146822 MI vs Clean 
NM_182569 A_24_P918891 Homo sapiens cDNA FLJ26323 fis, clone 
HRT00813, highly similar to Tissue factor 
pathway inhibitor 2 precursor (TFPI-2) 
MI vs Clean 
NM_032932 A_24_P401909 Homo sapiens hypothetical protein FLJ10781 
(FLJ10781), mRNA 
MI vs Clean 
NM_002851 A_24_P235248 Homo sapiens myelin transcription factor 1, 
mRNA (cDNA clone MGC:71389 
IMAGE:4301464), complete cds. 
MI vs Clean 
NM_178037 A_24_P162293 Homo sapiens mRNA; cDNA 
DKFZp667C0715 (from clone 
DKFZp667C0715) 
MI vs Clean 
NM_001906 A_23_P431139 Homo sapiens chymotrypsinogen B1 
(CTRB1), mRNA 
MI vs Clean 


Table 3. 162 Candidate genes identified in first microarray analysis 


NCBI ID Agilent ID Title Line Custom Whole Genome 
NM_001816 A_23_P380240 Homo sapiens mRNA; cDNA 
DKFZp686N1056 (from clone 
DKFZp686N1056). 
MI vs Clean 
NM_021936 A_23_P341966 Homo sapiens placenta-specific 3 (PLAC3), 
transcript variant 2, mRNA 
MI vs Clean 
NM_022076 A_23_P256077 Homo sapiens dual specificity phosphatase 21 
(DUSP21), mRNA 
MI vs Clean 
NM_019079 A_23_P137484 Homo sapiens PRO2207 mRNA, complete 
cds 
MI vs Clean 
BM980347 lit.v.00131_874 Homo sapiens cDNA FLJ35663 fis, clone 
SPLEN2017643, mRNA sequence 
1.3 MI v Clean 
(custom Clone 
NM_033034 lib.v.00142_1668 tripartite motif-containing 5 1.3 MI v Clean 
(custom Clone 
A_23_P48325 A_23_P48325 Unknown 1.3 Stenotic v 
Clean 
NM_033124 A_23_P47904 Homo sapiens NYD-SP28 protein (NYDSP28), 
mRNA [NM_033124] 
1.3 Stenotic v 
Clean 
NM_153011 A_23_P390634 Homo sapiens hypothetical protein FLJ30594 
(FLJ30594), mRNA [NM_153011] 
1.5 MI v Clean 
NM_080747 A_23_P336648 Homo sapiens keratin protein K6irs (K6IRS2), 
mRNA [NM_080747] 
1.5 MI v Clean 
NM_001974 A_23_P27556 Homo sapiens egf-like module containing, 
mucin-like, hormone receptor-like 1 (EMR1), 
mRNA [NM_001974] 
1.5 MI v Clean 
NM_003970 A_23_P258912 Homo sapiens myomesin (M-protein) 2, 
165kDa (MYOM2), mRNA [NM_003970] 
1.5 MI v Clean 
A_23_P250019 A_23_P250019 Unknown 1.5 MI v Clean 
NM_022843 A_23_P204885 Homo sapiens protocadherin 20 (PCDH20), 
mRNA [NM_022843] 
1.5 MI v Clean 
NM_002402 A_23_P156970 Homo sapiens mesoderm specific transcript 
homolog (mouse) (MEST), transcript variant 
1, mRNA [NM_002402] 
1.3 Stenotic v 
Clean 
NM_024660 A_23_P142424 Homo sapiens hypothetical protein FLJ22573 
(FLJ22573), mRNA [NM_024660] 
1.5 MI v Clean 
NM_005842 A_23_P128698 Homo sapiens sprouty homolog 2 
(Drosophila) (SPRY2), mRNA [NM_005842] 
1.3 Stenotic v 
Clean 
NM_015991 A_23_P114678 Homo sapiens complement component 1, q 
subcomponent, alpha polypeptide (C1QA), 
mRNA [NM_015991] 
1.5 MI v Clean 


Table 4. 107 significant genes identified in second microarray analysis 


NCBI ID Agilent ID Title Line Whole 
Genome 
fold pvalue 
NM_002619 A_24_P79403 Homo sapiens platelet factor 4 
(chemokine (C-X-C motif) ligand 4) 
(PF4), mRNA [NM_002619] 
Un vs Con 0.643 0.00223 
NM_002965 A_23_P23048 Homo sapiens S100 calcium binding protein 
A9 (calgranulin B) (S100A9), mRNA 
[NM_002965] 
St vs Con 1.557 0.0038 
BI026064 A_32_P112452 BI026064 CM0-MT0374-060201-774-h11 
MT0374 Homo sapiens cDNA, mRNA 
sequence [BI026064] 
St vs Con 1.5 0.0077 
AJ243670 A_24_P933838 Homo sapiens partial partial mRNA for 
NICE-4 protein, clone 3114f17. [AJ243670] 
Un vs Con 1.533 0.000813 
NM_003520 A_23_P402081 Homo sapiens histone 1, H2bn 
(HIST1H2BN), mRNA [NM_003520] 
Un vs Con 0.653 0.00161 
NM_003527 A_23_P59069 Homo sapiens histone 1, H2bo 
(HIST1H2BO), mRNA [NM_003527] 
Un vs Con 0.664 0.00223 
NM_004441 A_23_P166993 Homo sapiens EPH receptor B1 (EPHB1), 
mRNA [NM_004441] 
Un vs Con 1.733 0.000682 
NM_004441 A_23_P166993 Homo sapiens EPH receptor B1 (EPHB1), 
mRNA [NM_004441] 
Un vs St 1.606 0.00687 
NM_005621 A_23_P74001 Homo sapiens S100 calcium binding protein 
A12 (calgranulin C) (S100A12), mRNA 
[NM_005621] 
St vs Con 1.729 0.00111 
NM_005621 A_23_P74001 Homo sapiens S100 calcium binding protein 
A12 (calgranulin C) (S100A12), mRNA 
[NM_005621] 
Un vs Con 1.543 0.0036 
NM_014895 A_24_P337546 Homo sapiens chromosome 6 open reading 
frame 84 (C6orf84), mRNA [NM_014895] 
Un vs Con 1.842 0.00262 
NM_033655 A_23_P9135 Homo sapiens contactin associated protein-
like 3 (CNTNAP3), mRNA [NM_033655] 
Un vs Con 1.816 0.00568 
NM_199427 A_23_P120467 Homo sapiens zinc finger protein 64 homolog 
(mouse) (ZFP64), transcript variant 4, mRNA 
[NM_199427] 
Un vs Con 1.631 0.000813 
NM_014731 A_23_P380298 Homo sapiens ProSAPiP1 protein 
(ProSAPiP1), mRNA [NM_014731] 
St vs Con 0.597 0.000939 
BM929941 A_23_P212626 BM929941 UI-E-EJ1-aji-j-16-0-UI.r1 UI-EEJ1 
Homo sapiens cDNA clone UI-E-EJ1-aji-
j-16-0-UI 5', mRNA sequence [BM929941] 
St vs Con 0.662 0.00111 
NM_080912 A_23_P130113 Homo sapiens asialoglycoprotein receptor 2 
(ASGR2), transcript variant H2', mRNA 
[NM_080912] 
St vs Con 1.636 0.00242 
NM_004568 A_23_P70355 Homo sapiens serine (or cysteine) proteinase 
inhibitor, clade B (ovalbumin), member 6 
(SERPINB6), mRNA [NM_004568] 
St vs Con 1.622 0.00882 
NM_004568 A_24_P838743 Homo sapiens serine (or cysteine) proteinase 
inhibitor, clade B (ovalbumin), member 6 
(SERPINB6), mRNA [NM_004568] 
St vs Con 1.553 0.00242 
NM_172247 A_23_P136173 Homo sapiens colony stimulating factor 2 
receptor, alpha, low-affinity (granulocytemacrophage) 
(CSF2RA), transcript variant 4, 
mRNA [NM_172247] 
St vs Con 1.518 0.00328 
NM_001047 A_23_P30223 Homo sapiens steroid-5-alpha-reductase, 
alpha polypeptide 1 (3-oxo-5 alpha-steroid 
St vs Con 1.604 0.00439 


Table 4. 107 significant genes identified in second microarray analysis 


NCBI ID Agilent ID Title Line Whole 
Genome 
fold pvalue 
delta 4-dehydrogenase alpha 1) (SRD5A1), 
mRNA [NM_001047] 
NM_001731 A_23_P87560 Homo sapiens B-cell translocation gene 1, 
anti-proliferative (BTG1), mRNA 
[NM_001731] 
St vs Con 0.633 0.00584 
NM_178507 A_23_P310590 Homo sapiens NS5ATP13TP2 protein 
(NS5ATP13TP2), mRNA [NM_178507] 
St vs Con 1.669 0.0101 
NM_178507 A_24_P391586 Homo sapiens NS5ATP13TP2 protein 
(NS5ATP13TP2), mRNA [NM_178507] 
St vs Con 1.558 0.0482 
NM_002964 A_23_P434809 Homo sapiens S100 calcium binding protein 
A8 (calgranulin A) (S100A8), mRNA 
[NM_002964] 
St vs Con 1.648 0.0101 
NM_173842 A_23_P209995 Homo sapiens interleukin 1 receptor 
antagonist (IL1RN), transcript variant 1, 
mRNA [NM_173842] 
St vs Con 1.507 0.0274 
NM_012072 A_32_P56001 Homo sapiens complement component 1, q 
subcomponent, receptor 1 (C1QR1), mRNA 
[NM_012072] 
St vs Con 1.533 0.0115 
NM_182898 A_23_P157117 Homo sapiens cAMP responsive element 
binding protein 5 (CREB5), transcript variant 
1, mRNA [NM_182898] 
St vs Con 1.511 0.0308 
NM_016823 A_24_P270814 Homo sapiens v-crk sarcoma virus CT10 
oncogene homolog (avian) (CRK), transcript 
variant II, mRNA [NM_016823] 
St vs Con 1.601 0.0346 
NM_001911 A_23_P140384 Homo sapiens cathepsin G (CTSG), mRNA 
[NM_001911] 
St vs Con 1.737 0.0244 
NM_178519 A_24_P323084 Homo sapiens hypothetical protein FLJ39421 
(FLJ39421), mRNA [NM_178519] 
St vs Con 1.517 0.0387 
NM_147148 A_23_P217917 Homo sapiens glutathione S-transferase M4 
(GSTM4), transcript variant 2, mRNA 
[NM_147148] 
St vs Con 1.71 0.0169 
NM_005143 A_23_P206760 Homo sapiens haptoglobin (HP), mRNA 
[NM_005143] 
St vs Con 1.582 0.0191 
NM_000597 A_23_P119943 Homo sapiens insulin-like growth factor 
binding protein 2, 36kDa (IGFBP2), mRNA 
[NM_000597] 
St vs Con 1.628 0.0169 
NM_145791 A_23_P36658 Homo sapiens microsomal glutathione S-
transferase 1 (MGST1), transcript variant 1c, 
mRNA [NM_145791] 
St vs Con 1.58 0.0482 
NM_004577 A_23_P251984 Homo sapiens phosphoserine phosphatase 
(PSPH), mRNA [NM_004577] 
St vs Con 1.542 0.0346 
NM_002934 A_32_P1712 Homo sapiens ribonuclease, RNase A family, 
2 (liver, eosinophil-derived neurotoxin) 
(RNASE2), mRNA [NM_002934] 
St vs Con 1.673 0.0244 
NM_002934 A_32_P1712 Homo sapiens ribonuclease, RNase A family, 
2 (liver, eosinophil-derived neurotoxin) 
(RNASE2), mRNA [NM_002934] 
Un vs Con 1.631 0.00878 
NM_003942 A_23_P35791 Homo sapiens ribosomal protein S6 kinase, 
90kDa, polypeptide 4 (RPS6KA4), transcript 
variant 1, mRNA [NM_003942] 
St vs Con 1.507 0.0169 
NM_173078 A_32_P131640 Homo sapiens SLIT and NTRK-like family, 
member 4 (SLITRK4), mRNA [NM_173078] 
St vs Con 1.534 0.0387 
BG528379 A_24_P450493 BG528379 602557475F1 NIH_MGC_59 St vs Con 0.655 0.0115 


Table 4. 107 significant genes identified in second microarray analysis 


NCBI ID Agilent ID Title Line Whole 
Genome 
fold pvalue 
Homo sapiens cDNA clone IMAGE:4686330 
5', mRNA sequence [BG528379] 
NM_053044 A_23_P395438 Homo sapiens HtrA serine peptidase 3 
(HTRA3), mRNA [NM_053044] 
Un vs Con 1.615 0.00761 
NM_014505 A_23_P64792 Homo sapiens potassium large conductance 
calcium-activated channel, subfamily M, beta 
member 4 (KCNMB4), mRNA [NM_014505] 
Un vs Con 1.527 0.00878 
AF216862 A_24_P182122 Homo sapiens NADH dehydrogenase subnit 1 
mRNA, partial cds; mitochondrial gene for 
mitochondrial product. [AF216862] 
Un vs Con 0.567 0.00262 
NM_130782 A_23_P302550 Homo sapiens regulator of G-protein 
signalling 18 (RGS18), mRNA [NM_130782] 
Un vs Con 0.547 0.00115 
NM_145004 A_23_P44665 Homo sapiens a disintegrin and 
metalloproteinase domain 32 (ADAM32), 
mRNA [NM_145004] 
Un vs St 1.529 0.00605 
NM_004389 A_23_P84736 Homo sapiens catenin (cadherin-associated 
protein), alpha 2 (CTNNA2), mRNA 
[NM_004389] 
Un vs St 1.501 0.00897 
BC022297 A_24_P916927 Homo sapiens diacylglycerol kinase, epsilon 
64kDa, mRNA (cDNA clone 
IMAGE:4839690), complete cds. 
[BC022297] 
Un vs St 1.743 0.00774 
NM_005322 A_23_P250385 Homo sapiens histone 1, H1b (HIST1H1B), 
mRNA [NM_005322] 
Un vs St 1.797 0.000856 
NM_006865 A_23_P79094 Homo sapiens leukocyte immunoglobulin-
like receptor, subfamily A (without TM 
domain), member 3 (LILRA3), mRNA 
[NM_006865] 
Un vs St 0.514 0.00594 
NM_018314 A_24_P135193 Homo sapiens ubiquitin-conjugating enzyme 
E2-like (UEV3), mRNA [NM_018314] 
Un vs St 1.584 0.000236 
NM_007268 A_23_P217269 Homo sapiens V-set and immunoglobulin 
domain containing 4 (VSIG4), mRNA 
[NM_007268] 
Un vs St 2.013 0.00383 
NM_014220 A_24_P670942 CA441361 UI-H-DP0-avc-p-20-0-UI.s1 
NCI_CGAP_Fs1 Homo sapiens cDNA clone 
UI-H-DP0-avc-p-20-0-UI 3', mRNA 
sequence [CA441361] 
Un vs St 1.614 0.00154 
AF161365 A_24_P255415 Homo sapiens HSPC102 mRNA, partial cds. 
[AF161365] 
Un vs St 0.558 0.00552 
AK026903 A_23_P431853 Homo sapiens cDNA fis, A-COL04217, 
highly similar to Homo sapiens 
mitochondrion, NADH dehydrogenase 
subunit 2. [AK026903] 
Un vs Con 0.59 0.00761 
AK094117 A_32_P855872 Homo sapiens cDNA FLJ36798 fis, clone 
ADRGL2007283. [AK094117] 
Un vs Con 1.734 0.0042 
AY358137 A_23_P35494 Homo sapiens clone DNA193663 
VKGE9338 (UNQ9338) mRNA, complete 
cds. [AY358137] 
St vs Con 0.649 0.0115 
BC017379 A_23_P167983 Homo sapiens histone 1, H2ac, mRNA 
(cDNA clone MGC:1730 IMAGE:2988620), 
complete cds. [BC017379] 
Un vs Con 0.547 0.00658 
BC036403 A_24_P930015 Homo sapiens cDNA clone IMAGE:5265436, 
partial cds. [BC036403] 
Un vs St 1.758 0.00178 


Table 4. 107 significant genes identified in second microarray analysis 


NCBI ID Agilent ID Title Line Whole 
Genome 
fold pvalue 
CD633154 A_32_P172716 CD633154 56059439H1 FLP Homo sapiens 
cDNA, mRNA sequence [CD633154] 
Un vs St 1.624 0.00934 
CF529682 A_32_P888426 CF529682 UI-1-BC1p-asz-f-08-0-UI.s1 
NCI_CGAP_Pl3 Homo sapiens cDNA clone 
UI-1-BC1p-asz-f-08-0-UI 3', mRNA 
sequence [CF529682] 
Un vs St 1.563 0.00696 
CR740913 A_32_P75493 CR740913 Soares_testis_NHT Homo sapiens 
cDNA clone IMAGp971H2144 ; 
IMAGE:727364 5', mRNA sequence 
[CR740913] 
Un vs St 1.728 0.00964 
N52197 A_32_P3545 B25437 tubulin beta-2 chain - mouse 
(fragment) {Mus musculus;} , partial (18%) 
[THC2307581] 
Un vs Con 1.528 0.00878 
NM_001011543 A_23_P137007 Homo sapiens melanoma antigen family A, 
10 (MAGEA10), transcript variant 1, mRNA 
[NM_001011543] 
Un vs St 1.506 0.00474 
NM_005376 A_24_P156757 Homo sapiens v-myc myelocytomatosis viral 
oncogene homolog 1, lung carcinoma derived 
(avian) (MYCL1), mRNA [NM_005376] 
Un vs St 1.506 0.00841 
NM_005431 A_23_P134584 Homo sapiens X-ray repair complementing 
defective repair in Chinese hamster cells 2 
(XRCC2), mRNA [NM_005431] 
Un vs St 1.5 0.00761 
NM_006895 A_23_P56734 Homo sapiens histamine N-methyltransferase 
(HNMT), mRNA [NM_006895] 
St vs Con 1.546 0.0432 
NM_014256 A_23_P78980 Homo sapiens UDP-GlcNAc:betaGal beta-
1,3-N-acetylglucosaminyltransferase 3 
(B3GNT3), mRNA [NM_014256] 
Un vs Con 1.579 0.00568 
NM_014380 A_23_P45524 Homo sapiens nerve growth factor receptor 
(TNFRSF16) associated protein 1 
(NGFRAP1), transcript variant 3, mRNA 
[NM_014380] 
Un vs Con 0.588 0.00489 
NM_015314 A_23_P305205 Homo sapiens KIAA0895 protein 
(KIAA0895), mRNA [NM_015314] 
Un vs St 1.683 0.0041 
NM_139166 A_23_P313482 Homo sapiens striated muscle activator of 
Rho-dependent signaling (STARS), mRNA 
[NM_139166] 
Un vs St 1.549 0.00727 
NM_145168 A_23_P357838 Homo sapiens NAD(P) dependent steroid 
dehydrogenase-like (HSPC105), mRNA 
[NM_145168] 
Un vs St 1.601 0.00665 
NM_152401 A_23_P363301 Homo sapiens phosducin-like 2 (PDCL2), 
mRNA [NM_152401] 
Un vs St 1.582 0.00923 
NM_152776 A_23_P347562 Homo sapiens hypothetical protein 
MGC40579 (MGC40579), mRNA 
[NM_152776] 
Un vs Con 1.526 0.00658 
NM_153027 A_32_P193583 Homo sapiens hypothetical protein FLJ31659 
(FLJ31659), mRNA [NM_153027] 
Un vs St 1.543 0.00771 
NM_153244 A_32_P516067 Homo sapiens chromosome 10 open reading 
frame 111 (C10orf111), mRNA 
[NM_153244] 
Un vs St 1.506 0.00799 
NM_172004 A_23_P321984 Homo sapiens dendritic cell-associated lectin1 
(DCAL1), mRNA [NM_172004] 
Un vs St 1.709 0.00949 
NM_178173 A_24_P134765 Homo sapiens hypothetical protein 
LOC339834 (LOC339834), mRNA 
Un vs St 1.709 0.00793 


Table 4. 107 significant genes identified in second microarray analysis 


NCBI ID Agilent ID Title Line Whole 
Genome 
fold pvalue 
[NM_178173] 
NM_001003938 A_23_P15055 Homo sapiens hemoglobin mu chain (HBM), 
mRNA [NM_001003938] 
St vs Con 1.728 0.0432 
BQ446275 A_32_P47166 UI-H-EU1-baa-p-24-0-UI.s1 
NCI_CGAP_Ct1 Homo sapiens cDNA clone 
UI-H-EU1-baa-p-24-0-UI 3', mRNA 
sequence [BQ446275] 
St vs Con 1.982 0.0274 
NM_006121 A_23_P128235 Homo sapiens keratin 1 (epidermolytic 
hyperkeratosis) (KRT1), mRNA 
[NM_006121] 
Un vs Con 2.675 0.00568 
A_23_P317056 Un vs Con 0.57 0.00658 
NM_178353 A_23_P339691 Homo sapiens late cornified envelope 1E 
(LCE1E), mRNA [NM_178353] 
Un vs St 1.508 0.00956 
AF336873 A_23_P404039 Homo sapiens FKSG46 (FKSG46) mRNA, 
complete cds. [AF336873] 
Un vs St 1.68 0.0067 
NM_021052 A_23_P59045 Homo sapiens histone 1, H2ae 
(HIST1H2AE), mRNA [NM_021052] 
Un vs Con 0.624 0.00489 
AK027150 A_24_P152582 Homo sapiens cDNA: FLJ23497 fis, clone 
LNG02604. [AK027150] 
Un vs Con 1.648 0.00136 
A_24_P229426 Un vs St 1.641 0.00427 
A_24_P263443 St vs Con 0.523 0.0346 
NM_001029 A_24_P289404 Homo sapiens ribosomal protein S26 
(RPS26), mRNA [NM_001029] 
St vs Con 0.508 0.0482 
XM_497062 A_24_P384483 PREDICTED: Homo sapiens similar to 
hypothetical protein (LOC441448), mRNA 
[XM_497062] 
Un vs St 1.595 0.00418 
A_24_P463658 Q8RWQ1 (Q8RWQ1) 
At2g44720/F16B22.21, partial (3%) 
[THC2380758] 
Un vs St 1.68 0.00214 
NM_001013672 A_24_P624439 Homo sapiens hypothetical gene supported by 
AK128660 (LOC400566), mRNA 
[NM_001013672] 
Un vs St 1.543 0.00653 
NM_001029 A_24_P638294 Homo sapiens ribosomal protein S26 
(RPS26), mRNA [NM_001029] 
St vs Con 0.53 0.0346 
NM_001029 A_24_P638294 Homo sapiens ribosomal protein S26 
(RPS26), mRNA [NM_001029] 
Un vs Con 0.445 0.00568 
AB011180XM_051081 A_24_P6494 Homo sapiens mRNA for KIAA0608 protein, 
partial cds. [AB011180] 
Un vs St 1.525 0.00889 
NM_001013651 A_24_P660811 Homo sapiens hypothetical gene supported by 
AK128318 (LOC389607), mRNA 
[NM_001013651] 
Un vs Con 0.637 0.00761 
A_24_P730088 Un vs St 1.701 0.00425 
A_24_P859859 1305349A cystic fibrosis antigen. {Homo 
sapiens;} , complete [THC2266672] 
St vs Con 1.726 0.0115 
A_24_P887092 Un vs St 1.533 0.00788 
A_24_P918875 Un vs Con 0.59 0.00878 
A_32_P114535 Un vs St 1.623 0.00701 
XM_497095 A_32_P168431 PREDICTED: Homo sapiens similar to 40S 
ribosomal protein S26 (LOC441486), mRNA 
[XM_497095] 
St vs Con 0.509 0.0274 
XM_497095 A_32_P168431 PREDICTED: Homo sapiens similar to 40S 
ribosomal protein S26 (LOC441486), mRNA 
Un vs Con 0.438 0.00761 


Table 4. 107 significant genes identified in second microarray analysis 


NCBI ID Agilent ID Title Line Whole 
Genome 
fold pvalue 
[XM_497095] 
XM_499133 A_32_P24877 PREDICTED: Homo sapiens LOC441392 
(LOC441392), mRNA [XM_499133] 
Un vs Con 0.536 0.00223 
BX116511XM_295017 A_32_P26401 BX116511 Soares_testis_NHT Homo sapiens 
cDNA clone IMAGp998O031825, mRNA 
sequence [BX116511] 
Un vs St 1.73 0.00876 
AK024243 A_32_P3131 Homo sapiens cDNA FLJ14181 fis, clone 
NT2RP2004300. [AK024243] 
St vs Con 1.593 0.0169 
XM_208319 A_32_P721983 Similar to Epidermal Langerhans cell protein 
LCP1 
Un vs St 1.509 0.00155 
A_32_P72572 Un vs St 1.636 0.00133 


Table 5: List of 88 Genes for Plate 1 of initial RT-PCR screening 


Ref Seq ID Description Gene 
Symbol 
CDX ID Source Pairwise 
NM_001150 Homo sapiens alanyl (membrane) 
aminopeptidase (aminopeptidase N, 
aminopeptidase M, microsomal 
aminopeptidase, CD13, p150) 
(ANPEP), mRNA 
ANPEP NM_001150_1 Array 1 Stable vs. Control 
NM_031305 Homo sapiens Rho GTPase activating 
protein 24 (ARHGAP24), mRNA 
ARHGAP24 NM_031305_2 Array 1 Unstable vs Stable 
NM_020682 Homo sapiens Cyt19 protein 
(CYT19), mRNA 
AS3MT NM_020682_1 Array 1 Unstable vs Control 
NM_024837 Homo sapiens mRNA for KIAA1939 
protein 
ATP8B4 NM_024837_1 Array 1 Unstable vs Control 
NM_172215 Homo sapiens calcium/calmodulindependent 
protein kinase kinase 2, 
beta (CAMKK2), transcript variant 6, 
mRNA [NM_172215] 
CAMKK2 CDXR0050 Array 1 1.5 Unstable v Control 
NM_004345 Homo sapiens cathelicidin 
antimicrobial peptide (CAMP), 
mRNA 
CAMP NM_004345_1 Array 1 Stable vs Control 
NM_138806 Homo sapiens cell surface 
glycoprotein receptor CD200 
(CD200R), transcript variant 1, 
mRNA 
CD200R CDXR0046 Array 1 Unstable vs Control 
NM_001937 Homo sapiens dermatopontin (DPT), 
mRNA [NM_001937] 
DPT CDXR0016 Array 1 1.3 Unstable v Stable 
NM_016633 Homo sapiens erythroid associated 
factor (ERAF), mRNA 
ERAF NM_016633_1 Array 1 Unstable vs Control 
NM_000140 ferrochelatase (protoporphyria) FECH CDXR0002 Array 1 1.3 Unstable v Control 
(custom clone) 
NM_004114 Homo sapiens fibroblast growth 
factor 13 (FGF13), transcript variant 
1A, mRNA 
FGF13 CDXR0028 Array 1 Unstable vs Control 
NM_144682 Homo sapiens likely ortholog of 
mouse schlafen 10 (FLJ31952), 
mRNA 
FLJ31952 CDXR0047 Array 1 Unstable vs Control 
NM_001482 Homo sapiens glycine 
amidinotransferase (Larginine:
glycine amidinotransferase) 
(GATM), mRNA 
GATM NM_001482_1 Array 1 Unstable vs Stable 
NM_000519 Homo sapiens hemoglobin, delta 
(HBD), mRNA 
HBD NM_000519_1 Array 1 Unstable vs Control 
NG_000006 Homo sapiens alpha globin region 
(HBA@) on chromosome 16 
HBM NG_000006_1 Array 1 Unstable vs Control 
NM_004633 Homo sapiens interleukin 1 receptor, 
type II (IL1R2), transcript variant 1, 
mRNA 
ILR2 NM_004633_1 Array 1 Unstable vs Stable 
NM_004235 Homo sapiens Kruppel-like factor 4 
(gut) (KLF4), mRNA [NM_004235] 
KLF4 CDXR0029 Array 1 1.3 Stable v Control 
NM_002337 Homo sapiens low density lipoprotein 
receptor-related protein associated 
protein 1 (LRPAP1), mRNA 
LRPAP1 NM_002337_1 Array 1 Stable vs Control 


Table 5: List of 88 Genes for Plate 1 of initial RT-PCR screening 


Ref Seq ID Description Gene 
Symbol 
CDX ID Source Pairwise 
NM_016447 Homo sapiens membrane protein, 
palmitoylated 6 (MAGUK p55 
subfamily member 6) (MPP6), 
mRNA [NM_016447] 
MPP6 CDXR0037 Array 1 1.3 Unstable v Stable 
NM_001007225 Homo sapiens hepatocellular 
carcinoma autoantigen (p62) mRNA, 
complete cds 
P62 CDXR0011 Array 1 Plaque vs Control, 
Unstable vs Control 
NM_006194 Human PAX-9 mRNA, partial cds PAX9 NM_006194_1 Array 1 Unstable vs Control 
NM_153021 Homo sapiens phospholipase B1 
(PLB1), mRNA 
PLB1 CDXR0048 Array 1 Unstable vs Control 
NM_018211 Homo sapiens mRNA for KIAA1579 
protein, partial cds 
RAVER2 CDXR0039 Array 1 Unstable vs Control 
NM_002957 Homo sapiens retinoid X receptor, 
alpha (RXRA), mRNA 
RXRA NM_002957_1 Array 1 Stable vs Control 
NM_021977 Homo sapiens solute carrier family 22 
(extraneuronal monoamine 
transporter), member 3 (SLC22A3), 
mRNA 
SLC22A3 CDXR0042 Array 1 Unstable vs Control 
NM_033071 Homo sapiens mRNA for KIAA1756 
protein, partial cds 
SYNE1 CDXR0045 Array 1 Unstable vs Control 
NM_003236 Homo sapiens transforming growth 
factor, alpha (TGFA), mRNA 
TGFA CDXR0023 Array 1 Unstable vs Control 
NM_000119 Homo sapiens erythrocyte membrane 
protein band 4.2 (EPB42), mRNA 
EPB42 NM_000119_1 Array 1 (& 
Array 2) 
Unstable vs Control 
NM_006121 Homo sapiens keratin 1 
(epidermolytic hyperkeratosis) 
(KRT1), mRNA 
KRT1 NM_006121_2 Array 1 (& 
Array 2) 
Unstable vs Control 
NM_033125 Homo sapiens solute carrier family 22 
(organic cation transporter), member 
16 (SLC22A16), mRNA 
[NM_033125] 
SLC22A16 NM_033125_1 Array 1 (& 
Array 2) 
Unstable vs Stable 
NM_080912 Homo sapiens asialoglycoprotein 
receptor 2 (ASGR2), transcript 
variant H2, mRNA [NM_080912] 
ASGR2 CDXR0063 Array 2 St vs Con 
NM_001731 Homo sapiens B-cell translocation 
gene 1, anti-proliferative (BTG1), 
mRNA [NM_001731] 
BTG1 CDXR0067 Array 2 St vs Con 
#N/A #N/A C17orf55 CDXR0108 Array 2 St vs Con 
NM_012072 Homo sapiens complement 
component 1, q subcomponent, 
receptor 1 (C1QR1), mRNA 
[NM_012072] 
C1QR1 CDXR0095 Array 2 St vs Con 
NM_014895 Homo sapiens chromosome 6 open 
reading frame 84 (C6orf84), mRNA 
[NM_014895] 
C6orf84 CDXR0057 Array 2 Un vs Con 
NM_033655 Homo sapiens contactin associated 
protein-like 3 (CNTNAP3), mRNA 
[NM_033655] 
CNTNAP3 CDXR0058 Array 2 Un vs Con 
NM_182898 Homo sapiens cAMP responsive 
element binding protein 5 (CREB5), 
transcript varlant 1, mRNA 
[NM_182898] 
CREB5 CDXR0096 Array 2 St vs Con 

2 



Table 5: List of 88 Genes for Plate 1 of initial RT-PCR screening 


Ref Seq ID Description Gene 
Symbol 
CDX ID Source Pairwise 
NM_016823 Homo sapiens v-crk sarcoma virus 
CT10 oncogene homolog (avian) 
(CRK), transcript variant II, mRNA 
[NM_016823] 
CRK CDXR0097 Array 2 St vs Con 
NM_172247 Homo sapiens colony stimulating 
factor 2 receptor, alpha, low-affinity 
(granulocyte-macrophage) 
(CSF2RA), transcript variant 4, 
mRNA [NM_172247] 
CSF2RA CDXR0065 Array 2 St vs Con 
NM_001911 Homo sapiens cathepsin G (CTSG), 
mRNA [NM_001911] 
CTSG CDXR0098 Array 2 St vs Con 
BC022297 Homo sapiens diacylglycerol kinase, 
epsilon 64kDa, mRNA (cDNA clone 
IMAGE:4839690), complete cds, 
[BC022297] 
DGKE CDXR0115 Array 2 Un vs St 
NM_004441 Homo sapiens EPH receptor B1 
(EPHB1), mRNA [NM_004441] 
EPHB1 CDXR0055 Array 2 Un vs Con 
NM_147148 Homo sapiens glutathione S-
transferase M4 (GSTM4), transcript 
variant 2, mRNA [NM_147148] 
GSTM4 CDXR0100 Array 2 St vs Con 
NM_003520 Homo sapiens histone 1, H2bn 
(HIST1H2BN), mRNA 
[NM_003520] 
HIST1H2BN CDXR0053 Array 2 Un vs Con 
NM_003527 Homo sapiens histone 1, H2bo 
(HIST1H2BO), mRNA 
[NM_003527] 
HIST1H2BO CDXR0054 Array 2 Un vs Con 
NM_005143 Homo sapiens haptoglobin (HP), 
mRNA [NM_005143] 
HP CDXR0101 Array 2 St vs Con 
NM_014505 Homo sapiens potassium large 
conductance calcium-activated 
channel, subfamily M, beta member 4 
(KCNMB4), mRNA [NM_014505] 
KCNMB4 CDXR0110 Array 2 Un vs Con 
NM_006865 Homo sapiens leukocyte 
immunoglobulin-like receptor, 
subfamily A (without TM domain), 
member 3 (LILRA3), mRNA 
[NM_006865] 
LILRA3 CDXR0117 Array 2 Un vs St 
NM_145791 Homo sapiens microsomal 
glutathione S-transferase 1 (MGST1), 
transcript variant 1c, mRNA 
[NM_145791] 
MGST1 CDXR0103 Array 2 St vs Con 
#N/A #N/A NDST1 CDXR0052 Array 2 St vs Con 
NM_178507 Homo sapiens NS5ATP13TP2 protein 
(NS5ATP13TP2), mRNA 
[NM_178507] 
NS5ATP13TP2 CDXR0068 Array 2 St vs Con 
NM_014731 Homo sapiens ProSAPiP1 protein 
(ProSAPiP1), mRNA [NM_014731] 
ProSAPiP1 CDXR0061 Array 2 St vs Con 
NM_130782 Homo sapiens regulator of G-protein 
signaling 18 (RGS18), mRNA 
[NM_130782] 
RGS18 CDXR0112 Array 2 Un vs Con 

3 



Table 5: List of 88 Genes for Plate 1 of initial RT-PCR screening 


Ref Seq ID Description Gene 
Symbol 
CDX ID Source Pairwise 
NM_002934 Homo sapiens ribonuclease, RNase A 
family, 2 (liver, eosinophil-derived 
neurotoxin) (RNASE2), mRNA 
[NM_002934] 
RNASE2 CDXR0105 Array 2 St vs Con 
NM_003942 Homo sapiens ribosomal protein S6 
kinase, 90kDa, polypeptide 4 
(RPS6KA4), transcript variant 1, 
mRNA [NM_003942] 
RPS6KA4 CDXR0106 Array 2 St vs Con 
NM_005621 Homo sapiens S100 calcium binding 
protein A12 (calgranulin C) 
(S100A12), mRNA [NM_005621] 
S100A12 CDXR0056 Array 2 St vs Con 
NM_002964 Homo sapiens S100 calcium binding 
protein A8 (calgranulin A) (S100A8), 
mRNA [NM_002964] 
S100AB CDXR0069 Array 2 St vs Con 
NM_004568 Homo sapiens serien (or cysteine) 
proteinase inhibitor, clade B 
(ovalbumin), member 6 (SERPINB6), 
mRNA [NM_004568] 
SERPINB6 CDXR0064 Array 2 St vs Con 
AJ243670 Homo sapiens partial partial mRNA 
for NICE-4 protein, clone 3114f17. 
[AJ243670] 
UBAP2L CDXR0051 Array 2 Un vs Con 
NM_007268 Homo sapiens V-set and 
immunoglobulin domain containing 4 
(VSIG4), mRNA [NM_007268] 
VSIG4 CDXR0119 Array 2 Un vs St 
NM_001747 capping protein (actin filament), 
gelsolin-like 
CAPG CDXR0071 Literature NA 
NM_170662 Cas-Br-M (murine) ecotropic 
retroviral transforming sequence b 
CBLB CDXR0049 Literature NA 
NM_002982 chemokine (C-C motif) ligand 2 CCL2 NM_002982_2 Literature NA 
NM_000616 CD4 antigen (p55) CD4 CDXR0005 Literature NA 
NM_000074 CD40 ligand (TNF superfamily, 
member 5, hyper-IgM syndrome) 
CD40L CDXR0001 Literature NA 
NM_171827 CD8 antigen, alpha polypeptide (p32) CD8A CDXR0089 Literature NA 
NM_000395 colony stimulating factor 2 receptor, 
beta, low-affinity (granulocytemacrophage) 
CSF2RB CDXR0073 Literature NA 
NM_004385 chondroitin sulfate proteoglycan 2 
(versican) 
CSPG2 CDXR0074 Literature NA 
NM_000130 coagulation factor V (proaccelerin, 
labile factor) 
F5 CDXR0076 Literature NA 
NM_006433 granulysin GNLY CDXR0090 Literature NA 
NM_003516 histone 2, H2aa HIST2H2AA CDXR0094 Literature NA 
NM_002115 hexokinase 3 (white cell) HK3 CDXR0077 Literature NA 
NM_000619 interferon, gamma IFNG CDXR0079 Literature NA 
NM_003853 interleukin 18 receptor accessory 
protein 
IL18RAP CDXR0080 Literature NA 
NM_000576 interleukin 1, beta IL1B NM_000576_2 Literature NA 
NM_173841 interleukin 1 receptor antagonist IL1RN CDXR0081 Literature NA 
NM_002185 interleukin 7 receptor IL7R CDXR0082 Literature NA 

4 



Table 5: List of 88 Genes for Plate 1 of initial RT-PCR screening 


Ref Seq ID Description Gene 
Symbol 
CDX ID Source Pairwise 
NM_000632 integrin, alpha M (complement 
component receptor 3, alpha; also 
known as CD11b (p170), macrophage 
antigen alpha polypeptide) 
ITGAM CDXR0006 Literature NA 
NM_005907 mannosidase, alpha, class 1A, 
member 1 
MAN1A1 CDXR0084 Literature NA 
NM_005084.2 phospholipase A2, group VII 
(platelet-activating factor 
acetylhydrolase, plasma) 
PLA2G7 CDXR0086 Literature NA 
NM_003005 selectin P (granule membrane protein 
140kDa, antigen CD62) 
SELP CDXR0021 Literature NA 
NM_003612 semaphorin 7A, GPI membrane 
anchor (John Milton Hagen blood 
group) [Homo sapiens] 
SEMA7A CDXR0026 Literature NA 
NM_004612 transforming growth factor, beta 
receptor (activin A receptor type II-
like kinase, 53kDa) 
TGFBR1 CDXR0031 Literature NA 
NM_003242 transforming growth factor, beta 
receptor II (70/80kDa) 
TGFBR2 CDXR0024 Literature NA 
NM_003243 transforming growth factor, beta 
receptor III (betaglycan, 300kDa) 
TGFBR3 CDXR0025 Literature NA 
NM_000594 tumor necrosis factor (TNF 
superfamily, member 2) 
TNF NM_000594_1 Literature NA 
NM_001065 tumor necrosis factor receptor 
superfamily, member 1A 
TNFRSF1A CDXR0087 Literature NA 
NM_015397 WD repeat domain 40A [Homo 
sapiens] 
WDR40A CDXR0036 Literature NA 

5 



Table 6. Genes used in plate 2 of initial RT-PCR screening 


Accession # CDX ID Source 
AF161365 CDXR0121 Array 2 
AK002041 CDXR0123 Array 1 
AY358137 CDXR0131 Array 2 
AY358234 CDXR0132 Array 1 
BC017379 CDXR0133 Array 2 
CD633154 CDXR0135 Array 2 
CF529682 CDXR0136 Array 2 
ENST00000275874 CDXR0138 Array 1 
NM_000032 CDXR0142 Array 1 ( & Literature) 
NM_000201 CDXR0143 Literature 
NM_000201 CDXR0212 Literature 
NM_000419 CDXR0145 Literature 
NM_000572 CDXR0147 Literature 
NM_000591 CDXR0150 Literature 
NM_000594 CDXR0151 Literature 
NM_000634 CDXR0152 Literature 
NM_000639 CDXR0153 Literature 
NM_000655 CDXR0154 Literature 
NM_000660 CDXR0155 Literature 
NM_000698 CDXR0156 Literature 
NM_000760 CDXR0157 Literature 
NM_001066 CDXR0159 Literature 
NM_001124 CDXR0161 Literature 
NM_001511 CDXR0162 Literature 
NM_001557 CDXR0163 Literature 
NM_001562 CDXR0164 Literature 
NM_002162 CDXR0167 Literature 
NM_002286 CDXR0168 Literature 
NM_002603 CDXR0170 Literature 
NM_002923 CDXR0220 Literature 
NM_002965 CDXR0173 Array 2 (& Literature) 
NM_002985 CDXR0174 Literature 
NM_003268 CDXR0175 Literature 
NM_003807 CDXR0176 Literature 
NM_003810 CDXR0177 Literature 
NM_004001 CDXR0180 Literature 
NM_004049 CDXR0181 Literature 
NM_004512 CDXR0183 Literature 
NM_004938 CDXR0184 Array 1 
NM_005195 CDXR0185 Literature 
NM_005211 CDXR0186 Literature 
NM_005468 CDXR0189 Array 1 
NM_005902 CDXR0190 Literature 
NM_006895 CDXR0192 Array 2 


Table 6. Genes used in plate 2 of initial RT-PCR screening 


Accession # CDX ID Source 
NM_013314 CDXR0193 Array 1 
NM_014380 CDXR0195 Array 2 
NM_021083 CDXR0198 Array 1 
NM_145168 CDXR0200 Array 2 
NM_152592 CDXR0202 Array 1 
NM_172004 CDXR0206 Array 2 
NM_175854 CDXR0207 Array 1 
NM_181453 CDXR0209 Array 1 
NM_001765 CDXR0014 Array 1 
NM_016562 NM_016562-TLR7 Array 1 
NM_001771 CDXR0015 Array 1 
NM_020211 CDXR0040 Array 1 
NM_001398 NM_001398-ECH1 Array 1 
NM_002703 NM_002703-PPAT Array 1 
NM_004577 CDXR0104 Array 2 
NM_021205 CDXR0041 Literature 
NM_000660 CDXR0093 Literature 
NM_025260 CDXR0043 Literature 
NM_000885 CDXR0007 Literature 
NM_001002265 CDXR0009 Literature 
NM_005018 CDXR0032 Literature 
NM_002619 CDXR0019 Literature 
NM_002089 CDXR0075 Literature 
NM_002608 CDXR0085 Literature 
NM_002922 CDXR0092 Literature 


Table 7. Genes showing a p value of 0.05 across plates 1 and 2 in intial RT-PCR screening 
in example 4 

Gene NCBI FC p 
Av. 
Correlation 
Model 
Weight 
Abs. 
Model 
Weight 
CDXR0112.RGS18 NM_130782 0.83 0.0405 0.30 0.71 0.71 
CDXR0119.VSIG4 NM_007268 1.49 0.0004 0.25 -0.37 0.37 
CDXR0071.CAPG NM_001747 1.31 0.0000 0.60 -0.35 0.35 
CDXR0105.RNASE2 NM_002934 1.42 0.0001 0.55 -0.31 0.31 
CDXR0063.ASGR2 NM_080912 1.36 0.0011 0.49 -0.27 0.27 
CDXR0117.LILRA3 NM_006865 1.24 0.0055 0.44 -0.23 0.23 
CDXR0076.F5 NM_000130 1.24 0.0062 0.52 -0.22 0.22 
CDXR0081.IL1RN NM_173842 1.20 0.0130 0.60 0.20 0.20 
CDXR0065.CSF2RA NM_172247 1.34 0.0000 0.63 -0.20 0.20 
CDXR0056.S100A12 NM_005621 1.27 0.0046 0.49 -0.19 0.19 
CDXR0101.HP NM_005143 1.39 0.0358 0.30 -0.19 0.19 
CDXR0086.PLA2G7 NM_005084.2 1.20 0.0385 0.53 0.19 0.19 
CDXR0005.CD4 NM_000616 1.13 0.0158 0.58 0.18 0.18 
NM_016562.TLR7 NM_016562 1.23 0.0102 0.56 0.17 0.17 
CDXR0155.TGFB1 NM_000660 1.12 0.0221 0.50 -0.16 0.16 
CDXR0087.TNFRSF1A NM_001065 1.16 0.0028 0.61 -0.14 0.14 
CDXR0150.CD14 NM_000591 1.19 0.0394 0.61 0.13 0.13 
CDXR0175.TLR5 NM_003268 1.20 0.0086 0.66 0.12 0.12 
CDXR0075.CXCL2 NM_002089 1.33 0.0252 0.48 0.12 0.12 
CDXR0096.CREB5 NM_182898 1.23 0.0089 0.62 0.11 0.11 
CDXR0095.C1QR1 NM_012072 1.20 0.0062 0.65 0.10 0.10 
CDXR0074.CSPG2 NM_004385 1.36 0.0003 0.53 -0.10 0.10 
CDXR0014.CD1C NM_001765 1.20 0.0093 0.32 -0.10 0.10 
A23P208358.188.RPL28.1 A23P208358 1.09 0.0281 0.36 -0.10 0.10 
CDXR0052.NDST1 NM_001543 1.15 0.0223 0.61 0.09 0.09 
CDXR0048.PLB1 NM_153021 1.23 0.0062 0.57 -0.08 0.08 
CDXR0051.UBAP2L AJ243670 1.16 0.0098 0.46 -0.08 0.08 
CDXR0097.CRK NM_016823 1.16 0.0019 0.60 -0.08 0.08 
CDXR0167.ICAM3 NM_002162 1.09 0.0377 0.54 0.08 0.08 
CDXR0156.ALOX5 NM_000698 1.21 0.0020 0.67 -0.08 0.08 
CDXR0041.RHOU NM_021205 1.21 0.0025 0.55 -0.07 0.07 
CDXR0006.ITGAM NM_000632 1.18 0.0047 0.62 0.07 0.07 
CDXR0192.HNMT NM_006895 1.26 0.0041 0.64 0.07 0.07 
CDXR0185.CEBPD NM_005195 1.20 0.0365 0.57 0.07 0.07 
NM_002337_1.LRPAP1 NM_002337 1.12 0.0115 0.64 0.06 0.06 
CDXR0020.S100A9 NM_002965 1.19 0.0320 0.58 0.06 0.06 
CDXR0064.SERPINB6 NM_004568 1.12 0.0218 0.54 0.06 0.06 
CDXR0103.MGST1 NM_145791 1.34 0.0002 0.64 -0.05 0.05 
CDXR0184.DAPK1 NM_004938 1.19 0.0176 0.56 0.04 0.04 
CDXR0106.RPS6KA4 NM_003942 1.17 0.0017 0.60 -0.04 0.04 
CDXR0029.KLF4 NM_004235 1.25 0.0056 0.57 -0.04 0.04 


Table 7. Genes showing a p value of 0.05 across plates 1 and 2 in intial RT-PCR screening 
in example 4 

Gene NCBI FC p 
Av. 
Correlation 
Model 
Weight 
Abs. 
Model 
Weight 
CDXR0164.IL18 NM_001562 1.24 0.0068 0.58 -0.03 0.03 
CDXR0077.HK3 NM_002115 1.24 0.0023 0.62 -0.02 0.02 
NM_002957_1.RXRA NM_002957 1.22 0.0011 0.66 -0.02 0.02 
CDXR0157.CSF3R NM_000760 1.18 0.0246 0.60 -0.01 0.01 
CDXR0068.NS5ATP13TP2 NM_178507 1.22 0.0010 0.66 0.01 0.01 
CDXR0069.S100A8 NM_002964 1.25 0.0080 0.60 0.00 0.00 
CDXR0212.ICAM1 NM_000201 1.18 0.0199 0.63 0.00 0.00 
CDXR0186.CSF1R NM_005211 1.17 0.0103 0.57 0.00 0.00 
CDXR0159.TNFRSF1B NM_001066 1.15 0.0130 0.61 0.00 0.00 
CDXR0173.S100A9 NM_002965 1.27 0.0092 0.57 0.00 0.00 


Table 8. Genes identified from RT-PCR initial screening from samples in Example 5 


Non-Array Only Genes NCBI ID FC p 
CDXR0005.CD4 NM_000616 1.165234 0.006383 
CDXR0006.ITGAM NM_000632 1.143616 0.02881 
CDXR0029.KLF4 NM_004235 1.253768 0.022525 
CDXR0048.PLB1 NM_153021 1.225885 0.018232 
CDXR0052.NDST1 NM_001543 1.19852 0.010357 
CDXR0063.ASGR2 NM_080912 1.290352 0.022441 
CDXR0065.CSF2RA NM_172247 1.253667 0.006076 
CDXR0068.NS5ATP13TP2 NM_178507 1.227986 0.005691 
CDXR0071.CAPG NM_001747 1.273734 0.001406 
CDXR0074.CSPG2 NM_004385 1.331118 0.004665 
CDXR0076.F5 NM_000130 1.199816 0.046092 
CDXR0077.HK3 NM_002115 1.233064 0.010784 
CDXR0081.IL1RN NM_173842 1.225925 0.016532 
CDXR0087.TNFRSF1A NM_001065 1.164244 0.004949 
CDXR0095.C1QR1 NM_012072 1.23382 0.003931 
CDXR0096.CREB5 NM_182898 1.20687 0.049969 
CDXR0097.CRK NM_016823 1.136281 0.025354 
CDXR0103.MGST1 NM_145791 1.247674 0.010747 
CDXR0105.RNASE2 NM_002934 1.373594 0.003257 
CDXR0106.RPS6KA4 NM_003942 1.200508 0.002358 
CDXR0117.LILRA3 NM_006865 1.293783 0.00322 
CDXR0119.VSIG4 NM_007268 1.438522 0.003971 
NM_002337_1.LRPAP1 NM_002337 1.107373 0.02231 
NM_002957_1.RXRA NM_002957 1.23155 0.002913 
NM_006194_1.PAX9 NM_006194 1.354429 0.047951 
A23P208358.188.RPL28.1 A23P208358 1.094736 0.045826 
CDXR0014.CD1C NM_001765 1.188145 0.045284 
CDXR0015.CD22 NM_001771 0.758884 0.007436 
CDXR0041.RHOU NM_021205 1.212292 0.007115 
CDXR0143.ICAM1 NM_000201 1.156594 0.042869 
CDXR0156.ALOX5 NM_000698 1.224675 0.005259 
CDXR0157.CSF3R NM_000760 1.191773 0.034112 
CDXR0159.TNFRSF1B NM_001066 1.164109 0.017273 
CDXR0164.IL18 NM_001562 1.214465 0.027152 
CDXR0170.PDE7A NM_002603 0.875524 0.046163 
CDXR0173.S100A9 NM_002965 1.255358 0.029322 
CDXR0184.DAPK1 NM_004938 1.195422 0.0346 
CDXR0186.CSF1R NM_005211 1.167556 0.035683 
CDXR0192.HNMT NM_006895 1.232569 0.021784 
CDXR0212.ICAM1 NM_000201 1.210487 0.016254 
NM_016562.TLR7 NM_016562 1.223192 0.033567 


Table 9. Clinical characteristics of Cohort 2 

Indication for 
Indication for cath is other 
Indication for Indication for cath is than CAD, Cardiomyopathy 
cath is ischemic cath is valvular congenital heart valve, Congenital or pericardial Valvular 
heart disease heart disease disease congenital heart disease disease disease finding 

* 

n INDIHD INDVHD INDCHD INDOTH INDSHOCK FICONG FICARD FIANYV 

Average ( SD) 

Control 47 1.080.27 10 1.440.53 00 00 00 0.040.29 
Stable 47 1.060.25 20 1.80.45 00 00 00 0.020.15 
Unstable 74 1.030.16 20 20 00 00 00 00 

"Unstable" but no CAD 16 10 00 00 00 00 
Unstable mild CAD 33 1.060.24 20 20 00 00 00 00 
Stable mild CAD 35 1.140.36 20 1.890.33 00 00 00 0.090.37 

Range ( SD) 

Control 1  2 1  2 0  0 0  0 0  0 0  2 
Stable 1  2 2  2 1  2 0  0 0  0 0  0 0  1 
Unstable 1  2 2  2 2  2 0  0 0  0 0  0 0  0 

"Unstable" but no CAD 1  1 0  0 0  0 0  0 0  0 
Unstable mild CAD 1  2 2  2 0  0 0  0 0  0 0  0 
Stable mild CAD 1  2 2  2 1  2 0  0 0  0 0  0 0  2 

Median 

Control 1 100 0 0 
Stable 12 200 0 0 
Unstable 1 2 200 0 0 

"Unstable" but no CAD 1 0 0 0 0 
Unstable mild CAD 1 2 0 0 0 0 
Stable mild CAD 1 2 2 0 0 0 0 

# (%)of entries numeric 

Control 40 (85%) 1 (2%) 0 (0%) 9 (19%) 47 (100%) 47 (100%) 47 (100%) 47 (100%
Stable 47 (100%) 2 (4%) 0 (0%) 5 (11%) 47 (100%) 47 (100%) 47 (100%) 47 (100%
Unstable 74 (100%) 2 (3%) 0 (0%) 5 (7%) 74 (100%) 74 (100%) 74 (100%) 74 (100%
"Unstable" but no CAD 16 (100%) 0 (0%) 0 (0%) 0 (0%) 16 (100%) 16 (100%) 16 (100%) 16 (100%
Unstable mild CAD 33 (100%) 1 (3%) 0 (0%) 3 (9%) 33 (100%) 33 (100%) 33 (100%) 33 (100%
Stable mild CAD 35 (100%) 2 (6%) 0 (0%) 9 (26%) 35 (100%) 35 (100%) 35 (100%) 35 (100%


TTEST 

Control vs Stable&Unstable 
Control vs Stable 
Control vs Unstable 



Table 9. Clinical characteristics of Cohort 2 

Hx of 
Hx of peripheral 
Mitral valve Hx of Hx of diabetes cerebrovascula vascular Hx of 
stenosis Aortic stenosis hypertension mellitus r dz disease hyperlipidemia Hx of smoking 

** ** 

FIMITV FIAORV BPPRED DM_PRED HXCRV HXPVD HYL_PRED SMK_PRED 

Average ( SD) 

Control 00 0.040.29 0.530.5 0.280.45 0.090.28 00 0.430.5 0.30.46 
Stable 00 0.020.15 0.660.48 0.430.5 0.090.28 0.090.28 0.620.49 0.360.49 
Unstable 00 00 0.770.42 0.360.48 0.140.34 0.090.29 0.660.48 0.590.49 

"Unstable" but no CAD 00 00 0.810.4 0.310.48 00 00 0.310.48 0.380.5 
Unstable mild CAD 00 00 0.70.47 0.270.45 0.060.24 00 0.580.5 0.610.5 
Stable mild CAD 00 0.090.37 0.690.47 0.40.5 0.030.17 0.030.17 0.660.48 0.40.5 

Range ( SD) 

Control 0  0 0  2 0  1 0  1 0  1 0  0 0  1 0  1 
Stable 0  0 0  1 0  1 0  1 0  1 0  1 0  1 0  1 
Unstable 0  0 0  0 0  1 0  1 0  1 0  1 0  1 0  1 

"Unstable" but no CAD 0  0 0  0 0  1 0  1 0  0 0  0 0  1 0  1 
Unstable mild CAD 0  0 0  0 0  1 0  1 0  1 0  0 0  1 0  1 
Stable mild CAD 0  0 0  2 0  1 0  1 0  1 0  1 0  1 0  1 

Median 

Control00 1 00000 
Stable00 1 00010 
Unstable00 1 00011 

"Unstable" but no CAD 0 0 1 0 0 0 0 0 
Unstable mild CAD 0 0 1 0 0 0 1 1 
Stable mild CAD0 0 1 0 0 0 1 0 

# (%)of entries numeric 

Control 47 (100%) 47 (100%) 47 (100%) 47 (100%) 47 (100%) 47 (100%) 47 (100%) 47 (100%
Stable 47 (100%) 47 (100%) 47 (100%) 47 (100%) 47 (100%) 47 (100%) 47 (100%) 47 (100%
Unstable 74 (100%) 74 (100%) 74 (100%) 74 (100%) 74 (100%) 74 (100%) 74 (100%) 74 (100%
"Unstable" but no CAD 16 (100%) 16 (100%) 16 (100%) 16 (100%) 16 (100%) 16 (100%) 16 (100%) 16 (100%
Unstable mild CAD 33 (100%) 33 (100%) 33 (100%) 33 (100%) 33 (100%) 33 (100%) 33 (100%) 33 (100%
Stable mild CAD 35 (100%) 35 (100%) 35 (100%) 35 (100%) 35 (100%) 35 (100%) 35 (100%) 35 (100%


TTEST 

Control vs Stable&Unstable 
Control vs Stable 
Control vs Unstable 



Table 9. Clinical characteristics of Cohort 2 

Percent Percent Percent Percent Percent 
stenosis of stenosis of stenosis of stenosis of stenosis of 
RCA LMCA LAD LCA Proximal LAD # prior MIs Date with time 

CMG RCAST LMCST LADST LCAST PRXLADST PREMI PRIMIND CATHDATE 

Average ( SD) 

Control #DIV/0! 0.321.24 0.321.24 1.382.26 0.471.57 0.321.24 00 698.3674.74 #DIV/0! 
Stable #DIV/0! 52.1336.92 14.3624.64 68.8325.39 48.3634.47 29.4732.24 00 675.3845.14 #DIV/0! 
Unstable #DIV/0! 61.4736.13 16.6422.78 67.0929.78 62.9735.93 28.5832.53 0.450.67 650.0435.67 #DIV/0! 
"Unstable" but no CAD #DIV/0! 0.631.71 00 0.942.02 00 00 0.060.25 653.1313.81 #DIV/0! 
Unstable mild CAD #DIV/0! 13.2413.88 3.2810.52 21.8214.67 12.1216.2 4.78.92 0.090.29 663.755.74 #DIV/0! 
Stable mild CAD #DIV/0! 11.3414.34 6.5711.99 24.3713.64 14.2915.91 5.579.98 00 689.266.27 #DIV/0! 


Range ( SD) 

Control 0  5 0  5 0  5 0  7 0  5 0  0 638  919 
Stable 0  100 0  75 0  100 0  100 0  100 0  0 638  846 
Unstable 0  100 0  75 0  100 0  100 0  100 0  3 615  846 

"Unstable" but no CAD 0  5 0  0 0  5 0  0 0  0 0  1 638  666 
Unstable mild CAD 0  50 0  50 0  50 0  50 0  25 0  1 621  897 
Stable mild CAD 0  50 0  50 0  50 0  50 0  25 0  0 638  895 

Median 

Control 000000666 
Stable 50 0 75 50 25 0666 
Unstable 75 0 75 75 25 0 638 

"Unstable" but no CAD 0 0 0 0 0 0 663 
Unstable mild CAD 7 0 25 5 0 0 663 
Stable mild CAD 5 0 25 5 0 0 666 

# (%)of entries numeric 

Control 0 (0%) 47 (100%) 47 (100%) 47 (100%) 47 (100%) 47 (100%) 47 (100%) 47 (100%) 0 (0%
Stable 0 (0%) 47 (100%) 47 (100%) 47 (100%) 47 (100%) 47 (100%) 47 (100%) 47 (100%) 0 (0%
Unstable 0 (0%) 74 (100%) 73 (99%) 74 (100%) 74 (100%) 74 (100%) 74 (100%) 74 (100%) 0 (0%
"Unstable" but no CAD 0 (0%) 16 (100%) 16 (100%) 16 (100%) 16 (100%) 16 (100%) 16 (100%) 16 (100%) 0 (0%
Unstable mild CAD 0 (0%) 33 (100%) 32 (97%) 33 (100%) 33 (100%) 33 (100%) 33 (100%) 33 (100%) 0 (0%
Stable mild CAD 0 (0%) 35 (100%) 35 (100%) 35 (100%) 35 (100%) 35 (100%) 35 (100%) 35 (100%) 0 (0%


TTEST *** *** *** *** *** *** 

Control vs Stable&Unstable 1.99187E-34 6.10431E-11 1.07461E-51 1.22298E-34 7.13202E-17 0.001492805 
Control vs Stable 1.36093E-12 0.000307711 8.73566E-23 1.84115E-12 1.46581E-07 0.075165879 
Control vs Unstable 2.65809E-23 4.49271E-08 4.15799E-30 5.76652E-24 1.3781E-10 0.000110012 



Table 9. Clinical characteristics of Cohort 2 

Sequential Coronary artery 
Date Duke cath Sex dominance 

Males 

EN DATE_ SEQNO RACE SEX CHSEX DRACE LOCATNHX CORPREP 

Average ( SD) 
Control 00728.6221435. #DIV/0! 1.060.25 1.610.67 0.70.46 #DIV/0! 2.243.17 10 2.060.53 
Stable 01398.5119076. #DIV/0! 1.060.25 1.180.44 0.340.48 #DIV/0! 1.180.44 10 20.29 
Unstable 91158.5412359. #DIV/0! 1.891.58 1.350.68 0.340.48 #DIV/0! 2.233.67 10 1.960.39 
"Unstable" but no CAD 639369212108.1 #DIV/0! 10 1.530.52 0.560.51 #DIV/0! 2.53.9 10 1.750.45 
Unstable mild CAD 90509.7316070. #DIV/0! 1.330.65 1.40.72 0.330.48 #DIV/0! 1.972.96 10 1.910.29 
Stable mild CAD 01798.1421012. #DIV/0! 1.140.43 1.380.65 0.460.51 #DIV/0! 1.380.65 10 1.970.51 

Range ( SD) 
Control372508  643541 1  2 1  4 0  1 1  17 1  1 1  3 
Stable372561  643519 1  2 1  3 0  1 1  3 1  1 1  3 
Unstable372410  643003 1  9 1  4 0  1 1  17 1  1 1  3 

"Unstable" but no CAD375750  641607 1  1 1  2 0  1 1  17 1  1 1  2 
Unstable mild CAD372197  643543 1  3 1  4 0  1 1  17 1  1 1  2 
Stable mild CAD373807  643522 1  3 1  3 0  1 1  3 1  1 1  3 

Median 

Control 6397030 1 2 1 2 1 2 
Stable6396756 1 1 0 1 1 2 
Unstable 6389612 1 1 0 1 1 2 

"Unstable" but no CAD 6390144 1 2 1 2 1 2 
Unstable mild CAD 6387560 1 1 0 1 1 2 
Stable mild CAD 6396392 1 1 0 1 1 2 

# (%)of entries numeric 

Control 47 (100%) 0 (0%) 47 (100%) 41 (87%) 47 (100%) 0 (0%) 42 (89%) 47 (100%) 47 (100%
Stable 47 (100%) 0 (0%) 47 (100%) 45 (96%) 47 (100%) 0 (0%) 45 (96%) 47 (100%) 47 (100%
Unstable 74 (100%) 0 (0%) 74 (100%) 69 (93%) 74 (100%) 0 (0%) 73 (99%) 74 (100%) 74 (100%
"Unstable" but no CAD 16 (100%) 0 (0%) 16 (100%) 15 (94%) 16 (100%) 0 (0%) 16 (100%) 16 (100%) 16 (100%
Unstable mild CAD 33 (100%) 0 (0%) 33 (100%) 30 (91%) 33 (100%) 0 (0%) 31 (94%) 33 (100%) 33 (100%
Stable mild CAD 35 (100%) 0 (0%) 35 (100%) 34 (97%) 35 (100%) 0 (0%) 34 (97%) 35 (100%) 35 (100%


TTEST ** *** *** * 

Control vs Stable&Unstable 0.109732772 7.74688E-05 0.007103574 0.468158283 
Control vs Stable 0.873196405 1 0.000801076 0.037347846 
Control vs Unstable 0.00706079 3.20479E-05 0.051380675 0.993617721 



Table 9. Clinical characteristics of Cohort 2 

Hx of 
Encounter Duration of Days from myocardial 
Age category symptoms most recent MI infarction Diabetes type 

* ** 

CORPREPF AGE FUP AGEC TMROCATH CAD_DUR DPMI HXMI DIABTYPE 

Average ( SD) 

Control 0.020.15 52.4911.07 00 53.0210.99 00 40.7592.7 #DIV/0! 00 20 
Stable 00 64.669.86 0.870.34 65.219.85 00 45.6766.27 #DIV/0! 00 1.950.22 
Unstable 0.120.33 62.8110.07 10 63.3710.05 00 51.5873.8 1100.961989.84 0.360.48 1.960.19 

"Unstable" but no CAD 00 49.9411.49 00 50.5211.52 00 4.6214.1 00 0.060.25 20 
Unstable mild CAD 0.030.17 57.2411.77 0.180.39 57.7611.79 00 24.2534.87 356584.83 0.090.29 1.890.33 
Stable mild CAD 00 58.238.44 0.060.24 58.728.34 00 51.4392.86 #DIV/0! 00 1.930.27 

Range ( SD) 
Control 0  1 29  73 0  0 29.92  73.47 0  0 0.03  425.95 0  0 2  2 
Stable 0  0 45  89 0  1 45.29  89.13 0  0 0  253.5 0  0 1  2 
Unstable 0  1 39  84 1  1 39.55  84.68 0  0 0.03  287.31 0  7270 0  1 1  2 

"Unstable" but no CAD 0  0 27  74 0  0 27.61  74.31 0  0 0.07  57 0  0 0  1 2  2 
Unstable mild CAD 0  1 36  83 0  1 36.96  83.3 0  0 0.03  128.43 1  1031 0  1 1  2 
Stable mild CAD 0  0 45  78 0  1 45.88  78.13 0  0 0.07  393.58 0  0 1  2 

Median 

Control054 055 0 5 0 2 
Stable062 163 019 0 2 
Unstable0 63 1 63 0 11 60 0 2 

"Unstable" but no CAD 0 48 0 48 0 0 0 2 
Unstable mild CAD 0 56 0 56 0 3 36 0 2 
Stable mild CAD 0 57 0 57 0 9 0 2 

# (%)of entries numeric 
Control 47 (100%) 47 (100%) 47 (100%) 47 (100%) 47 (100%) 36 (77%) 0 (0%) 47 (100%) 13 (28%) 
Stable 47 (100%) 47 (100%) 47 (100%) 47 (100%) 47 (100%) 38 (81%) 0 (0%) 47 (100%) 20 (43%) 
Unstable 74 (100%) 74 (100%) 74 (100%) 74 (100%) 74 (100%) 71 (96%) 27 (36%) 74 (100%) 27 (36%) 
"Unstable" but no CAD 16 (100%) 16 (100%) 16 (100%) 16 (100%) 16 (100%) 16 (100%) 1 (6%) 16 (100%) 5 (31%) 
Unstable mild CAD 33 (100%) 33 (100%) 33 (100%) 33 (100%) 33 (100%) 32 (97%) 3 (9%) 33 (100%) 9 (27%) 
Stable mild CAD 35 (100%) 35 (100%) 35 (100%) 35 (100%) 35 (100%) 26 (74%) 0 (0%) 35 (100%) 14 (40%) 

TTEST *** *** 
Control vs Stable&Unstable 7.23993E-08 5.90561E-08 0.605978781 
Control vs Stable 2.00441E-07 1.74688E-07 0.794758458 
Control vs Unstable 1.34995E-06 1.13701E-06 0.54464663 


Table 9. Clinical characteristics of Cohort 2 

Days from 
Days from Days from Days from previous Duke Days from 
Duke CAD most recent most recent previous ICC ICC lab Days from previous Duke 
CAD Class CAD index index PTCA Duke PTCA lab procedure procedure previous CABG CABG 

** 

CADCLASS CADINDEX DUKEINDX DPPTCA DPPTCAD DPICC DPICCD DPCABG DPCABGD 

Average ( SD) 

Control 00 00 00 #DIV/0! #DIV/0! #DIV/0! #DIV/0! #DIV/0! #DIV/0! 
Stable 5.573.35 41.8319.58 46.5723.14 #DIV/0! #DIV/0! #DIV/0! #DIV/0! #DIV/0! #DIV/0! 
Unstable 5.712.78 42.6617.41 48.6120.46 1573.741398.311511.641398.371573.741398.311511.641398.37 #DIV/0! #DIV/0! 
"Unstable" but no CAD 00 00 00 #DIV/0! #DIV/0! #DIV/0! #DIV/0! #DIV/0! #DIV/0! 
Unstable mild CAD 0.270.45 5.188.59 5.459.05 8681176.63 8681176.63 749857.15 749857.15 #DIV/0! #DIV/0! 
Stable mild CAD 0.310.47 5.978.95 6.299.42 #DIV/0! #DIV/0! #DIV/0! #DIV/0! #DIV/0! #DIV/0! 


Range ( SD) 

Control 0  0 0  0 0  0 
Stable 1  11 19  82 20  96 
Unstable 3  11 23  82 29  96 60  5160 60  5160 60  5160 60  5160 

"Unstable" but no CAD 0  0 0  0 0  0 
Unstable mild CAD 0  1 0  19 0  20 36  1700 36  1700 36  1700 36  1700 
Stable mild CAD 0  1 0  19 0  20 

Median 

Control 0 0 0 
Stable 4 32 31 
Unstable 5 37 43 1208 1172 1208 1172 

"Unstable" but no CAD 0 0 0 
Unstable mild CAD 0 0 0 868 868 511 511 
Stable mild CAD 0 0 0 

# (%)of entries numeric 

Control 47 (100%) 43 (91%) 47 (100%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%
Stable 28 (60%) 47 (100%) 47 (100%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%
Unstable 45 (61%) 74 (100%) 74 (100%) 23 (31%) 22 (30%) 23 (31%) 22 (30%) 0 (0%) 0 (0%
"Unstable" but no CAD 16 (100%) 16 (100%) 16 (100%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%
Unstable mild CAD 33 (100%) 33 (100%) 33 (100%) 2 (6%) 2 (6%) 3 (9%) 3 (9%) 0 (0%) 0 (0%
Stable mild CAD 35 (100%) 35 (100%) 35 (100%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%


TTEST *** *** *** 

Control vs Stable&Unstable 1.09221E-25 2.0878E-50 1.58119E-48 
Control vs Stable 2.03359E-09 6.14653E-19 5.77258E-18 
Control vs Unstable 1.37703E-17 9.20273E-33 6.30433E-32 



Table 9. Clinical characteristics of Cohort 2 

Days from most 
recent Congestive Hx of 
thrombolytic Days from previous Days from previous heart failure congestive 
therapy catheterization Duke catheterization Carotid bruit Height Weight severity heart failure 

* 

DPTHROM DPCATH DPCATHD CARBRUI HT WT CHF_SEV CHF 

Average ( SD) 

Control #DIV/0! 4053.251581.5 42161895.46 00 168.410.65 89.622.84 00 00 
Stable #DIV/0! 2448.61417.76 3403707.06 00 171.6310.62 85.3916.38 00 00 
Unstable 61580 1637.681796.67 1549.441711.92 0.080.49 172.0510.25 89.720.08 00 00 

"Unstable" but no CAD #DIV/0! #DIV/0! #DIV/0! 00 168.2511.25 98.424.36 00 00 
Unstable mild CAD #DIV/0! 731.4535.94 597.88496.35 00 173.6110.26 89.2720.91 00 00 
Stable mild CAD #DIV/0! 26292708.01 3127.252850.04 0.030.17 173.098.32 95.2621.11 00 00 

Range ( SD) 

Control 2409  6189 2409  6189 0  0 145  196 55  144 0  0 0  0 
Stable 694  3982 2615  3982 0  0 152  193 55  138 0  0 0  0 
Unstable 6158  6158 7  5760 7  5681 0  3 142  193 52  140 0  0 0  0 

"Unstable" but no CAD 0  0 152  193 53  131 0  0 0  0 
Unstable mild CAD 36  1537 36  1505 0  0 155  196 55  134 0  0 0  0 
Stable mild CAD 330  6552 330  6552 0  1 158  188 56  141 0  0 0  0 

Median 

Control 3808 4050 0 168 83 0 0 
Stable 2615 3612 0 173 86 0 0 
Unstable 899 808 0 173 89 0 0 

"Unstable" but no CAD 0 167 93 0 0 
Unstable mild CAD 662 480 0 175 87 0 0 
Stable mild CAD 1294 2814 0 173 92 0 0 

# (%)of entries numeric 
Control 0 (0%) 4 (9%) 3 (6%) 47 (100%) 47 (100%) 47 (100%) 47 (100%) 47 (100%) 
Stable 0 (0%) 5 (11%) 3 (6%) 47 (100%) 46 (98%) 46 (98%) 47 (100%) 47 (100%) 
Unstable 1 (1%) 34 (46%) 27 (36%) 74 (100%) 74 (100%) 74 (100%) 73 (99%) 73 (99%) 
"Unstable" but no CAD 0 (0%) 0 (0%) 0 (0%) 16 (100%) 16 (100%) 15 (94%) 16 (100%) 16 (100%) 
Unstable mild CAD 0 (0%) 10 (30%) 8 (24%) 33 (100%) 33 (100%) 33 (100%) 33 (100%) 33 (100%) 
Stable mild CAD 0 (0%) 5 (14%) 4 (11%) 34 (97%) 35 (100%) 35 (100%) 34 (97%) 34 (97%) 

TTEST * 
Control 
vs Stable&Unstable 0.05409434 0.142251408 0.058666341 0.681242858 
Control vs Stable 0.163020737 0.544530718 0.147148371 0.309907361 
Control vs Unstable 0.046953812 0.124578215 0.065420613 0.979084984 


Table 9. Clinical characteristics of Cohort 2 

Ejection History of Angina in the Continuous 
Transient CHF fraction Q-waves ST-T LVID angina last 6 weeks chest pain 

** 

CHFTRANS EJFX EKGQWV STTW STTLVID NO CPAIN CPAIN6WK CONCPAIN 

Average ( SD) 

Control 00 64.676.06 #DIV/0! #DIV/0! #DIV/0! 00 #DIV/0! #DIV/0! #DIV/0! 
Stable 00 63.369.12 #DIV/0! #DIV/0! #DIV/0! 1.470.95 #DIV/0! #DIV/0! #DIV/0! 
Unstable 00 62.199.55 #DIV/0! #DIV/0! #DIV/0! 1.760.79 #DIV/0! #DIV/0! #DIV/0! 
"Unstable" but no CAD 00 67.328.31 #DIV/0! #DIV/0! #DIV/0! 00 #DIV/0! #DIV/0! #DIV/0! 
Unstable mild CAD 00 65.0811.16 #DIV/0! #DIV/0! #DIV/0! 00 #DIV/0! #DIV/0! #DIV/0! 
Stable mild CAD 00 61.237.66 #DIV/0! #DIV/0! #DIV/0! 00 #DIV/0! #DIV/0! #DIV/0! 


Range ( SD) 

Control 0  0 52.82  77.33 0  
0 
Stable 0  0 44.32  79.07 0  
3 
Unstable 0  0 40.32  89.03 0  
3 


"Unstable" but no CAD 0  0 54.93  86.34 0  0 
Unstable mild CAD 0  0 40.14  88.45 0  0 
Stable mild CAD 0  0 43.1  77.67 0  0 

Median 

Control 0 64 0 
Stable 0 65 1 
Unstable 0 63 2 

"Unstable" but no CAD 0 67 0 
Unstable mild CAD 0 64 0 
Stable mild CAD 0 62 0 

# (%)of entries numeric 

Control 47 (100%) 47 (100%) 0 (0%) 0 (0%) 0 (0%) 43 (91%) 0 (0%) 0 (0%) 0 (0%
Stable 47 (100%) 47 (100%) 0 (0%) 0 (0%) 0 (0%) 47 (100%) 0 (0%) 0 (0%) 0 (0%
Unstable 73 (99%) 74 (100%) 0 (0%) 0 (0%) 0 (0%) 74 (100%) 0 (0%) 0 (0%) 0 (0%
"Unstable" but no CAD 16 (100%) 16 (100%) 0 (0%) 0 (0%) 0 (0%) 16 (100%) 0 (0%) 0 (0%) 0 (0%
Unstable mild CAD 33 (100%) 33 (100%) 0 (0%) 0 (0%) 0 (0%) 33 (100%) 0 (0%) 0 (0%) 0 (0%
Stable mild CAD 34 (97%) 35 (100%) 0 (0%) 0 (0%) 0 (0%) 35 (100%) 0 (0%) 0 (0%) 0 (0%


TTEST 



Control vs Stable&Unstable 0.100833111 
Control vs Stable 0.414424757 
Control vs Unstable 0.082628254 



Table 9. Clinical characteristics of Cohort 2 

Mitral 
Chest pain Chest pain Chest pain insufficiency 
severity frequency Chest pain type course grade COPD Charlson index 

CPAINSEV CPAINFRE PAINTYP CPAINCOR MITINS LVCNL COPD CHARLSON 

Average ( SD) 

Control 4.091.17 5.746.98 1.090.61 1.310.47 0.110.43 0.910.28 0.060.25 0.530.72 
Stable 3.341.14 4.834.85 1.340.59 1.570.5 0.170.48 0.70.46 0.060.25 11.06 
Unstable 4.081.04 4.475.98 1.590.55 30 0.160.57 0.510.5 0.030.16 0.730.85 


"Unstable" but no CAD 4.251.18 3.133.22 0.810.66 30 0.060.25 10 00 0.440.81 
Unstable mild CAD 4.580.71 5.367.92 1.210.74 30 0.030.17 0.850.36 0.060.24 0.390.56 
Stable mild CAD 4.161.07 6.249.58 1.120.6 1.280.54 0.20.53 0.890.32 0.110.32 0.710.86 

Range ( SD) 

Control 1  5 0  30 0  2 1  2 0  2 0  1 0  1 0  3 
Stable 1  5 0.15  28 0  2 1  2 0  2 0  1 0  1 0  4 
Unstable 2  5 1  50 0  2 3  3 0  3 0  1 0  1 0  4 

"Unstable" but no CAD 2  5 1  14 0  2 3  3 0  1 1  1 0  0 0  3 
Unstable mild CAD 2  5 1  35 0  2 3  3 0  1 0  1 0  1 0  2 
Stable mild CAD 2  5 0.5  49 0  2 0  2 0  2 0  1 0  1 0  3 

Median 

Control4311 0 100 
Stable3312 0 101 
Unstable4323 0 101 

"Unstable" but no CAD 5 3 1 3 0 1 0 0 
Unstable mild CAD 5 3 1 3 0 1 0 0 
Stable mild CAD5 3 1 1 0 1 0 1 

# (%)of entries numeric 

Control 35 (74%) 34 (72%) 35 (74%) 35 (74%) 47 (100%) 47 (100%) 47 (100%) 47 (100%
Stable 35 (74%) 35 (74%) 35 (74%) 35 (74%) 47 (100%) 47 (100%) 47 (100%) 47 (100%
Unstable 74 (100%) 73 (99%) 74 (100%) 74 (100%) 74 (100%) 74 (100%) 74 (100%) 74 (100%
"Unstable" but no CAD 16 (100%) 16 (100%) 16 (100%) 16 (100%) 16 (100%) 16 (100%) 16 (100%) 16 (100%
Unstable mild CAD 33 (100%) 33 (100%) 33 (100%) 33 (100%) 33 (100%) 33 (100%) 33 (100%) 33 (100%
Stable mild CAD 25 (71%) 25 (71%) 25 (71%) 25 (71%) 35 (100%) 35 (100%) 35 (100%) 35 (100%


TTEST ** * 

Control vs Stable&Unstable 0.288531654 0.38244822 0.027268586 
Control vs Stable 0.00893957 0.533034262 0.014389027 
Control vs Unstable 0.984158388 0.360999846 0.171957348 


Table 9. Clinical characteristics of Cohort 2 

Cardiovascular 
death Renal disease 

* 

DEMENTIA CTISDZ PEPULC LIVER_M CVD DIABETES HEMIPLEG RENALDZ 

Average ( SD) 

Control 00 0.040.2 00 00 0.090.28 0.260.44 00 0.020.15 
Stable 00 00 00 00 0.090.28 0.380.49 00 0.040.2 
Unstable 00 00 0.010.12 00 0.140.34 0.340.48 00 0.010.12 

"Unstable" but no CAD 00 00 00 00 00 0.310.48 00 00 
Unstable mild CAD 00 00 00 00 0.060.24 0.270.45 00 00 
Stable mild CAD 00 00 00 00 0.030.17 0.370.49 00 00 

Range ( SD) 

Control 0  0 0  1 0  0 0  0 0  1 0  1 0  0 0  1 
Stable 0  0 0  0 0  0 0  0 0  1 0  1 0  0 0  1 
Unstable 0  0 0  0 0  1 0  0 0  1 0  1 0  0 0  1 

"Unstable" but no CAD 0  0 0  0 0  0 0  0 0  0 0  1 0  0 0  0 
Unstable mild CAD 0  0 0  0 0  0 0  0 0  1 0  1 0  0 0  0 
Stable mild CAD 0  0 0  0 0  0 0  0 0  1 0  1 0  0 0  0 

Median 

Control0000 0 000 
Stable0000 0 000 
Unstable0000 0 000 

"Unstable" but no CAD 0 0 0 0 0 0 0 0 
Unstable mild CAD 0 0 0 0 0 0 0 0 
Stable mild CAD0 0 0 0 0 0 0 0 

# (%)of entries numeric 

Control 47 (100%) 47 (100%) 47 (100%) 47 (100%) 47 (100%) 47 (100%) 47 (100%) 47 (100%
Stable 47 (100%) 47 (100%) 47 (100%) 47 (100%) 47 (100%) 47 (100%) 47 (100%) 47 (100%
Unstable 74 (100%) 74 (100%) 74 (100%) 74 (100%) 74 (100%) 74 (100%) 74 (100%) 74 (100%
"Unstable" but no CAD 16 (100%) 16 (100%) 16 (100%) 16 (100%) 16 (100%) 16 (100%) 16 (100%) 16 (100%
Unstable mild CAD 33 (100%) 33 (100%) 33 (100%) 33 (100%) 33 (100%) 33 (100%) 33 (100%) 33 (100%
Stable mild CAD 35 (100%) 35 (100%) 35 (100%) 35 (100%) 35 (100%) 35 (100%) 35 (100%) 35 (100%


TTEST 

Control vs Stable&Unstable 
Control vs Stable 
Control vs Unstable 



Table 9. Clinical characteristics of Cohort 2 

Diabetes, w 
end organ 
damage IVCD 

DMENDORG TUMOR LEUKEMIA LYMPHOMA LIVER_S METASTAT PVD VENGALL EKGIVCD 

Average ( SD) 

Control 0.020.15 00 00 00 00 00 00 0.020.15 #DIV/0! 
Stable 0.040.2 0.060.25 00 00 0.020.15 00 0.110.31 00 #DIV/0! 
Unstable 0.030.16 0.010.12 00 00 00 00 0.110.31 00 #DIV/0! 
"Unstable" but no CAD 00 0.060.25 00 00 00 00 00 00 #DIV/0! 
Unstable mild CAD 00 00 00 00 00 00 00 00 #DIV/0! 
Stable mild CAD 0.030.17 0.060.24 00 00 00 00 0.030.17 00 #DIV/0! 


Range ( SD) 

Control 0  1 0  0 0  0 0  0 0  0 0  0 0  0 0  1 
Stable 0  1 0  1 0  0 0  0 0  1 0  0 0  1 0  0 
Unstable 0  1 0  1 0  0 0  0 0  0 0  0 0  1 0  0 

"Unstable" but no CAD 0  0 0  1 0  0 0  0 0  0 0  0 0  0 0  0 
Unstable mild CAD 0  0 0  0 0  0 0  0 0  0 0  0 0  0 0  0 
Stable mild CAD 0  1 0  1 0  0 0  0 0  0 0  0 0  1 0  0 

Median 

Control0 0 0 0 0 0 0 0 
Stable0 0 0 0 0 0 0 0 
Unstable0 0 0 0 0 0 0 0 

"Unstable" but no CAD 0 0 0 0 0 0 0 0 
Unstable mild CAD 0 0 0 0 0 0 0 0 
Stable mild CAD0 0 0 0 0 0 0 0 

# (%)of entries numeric 

Control 47 (100%) 47 (100%) 47 (100%) 47 (100%) 47 (100%) 47 (100%) 47 (100%) 47 (100%) 0 (0%
Stable 47 (100%) 47 (100%) 47 (100%) 47 (100%) 47 (100%) 47 (100%) 47 (100%) 47 (100%) 0 (0%
Unstable 74 (100%) 74 (100%) 74 (100%) 74 (100%) 74 (100%) 74 (100%) 74 (100%) 74 (100%) 0 (0%
"Unstable" but no CAD 16 (100%) 16 (100%) 16 (100%) 16 (100%) 16 (100%) 16 (100%) 16 (100%) 16 (100%) 0 (0%
Unstable mild CAD 33 (100%) 33 (100%) 33 (100%) 33 (100%) 33 (100%) 33 (100%) 33 (100%) 33 (100%) 0 (0%
Stable mild CAD 35 (100%) 35 (100%) 35 (100%) 35 (100%) 35 (100%) 35 (100%) 35 (100%) 35 (100%) 0 (0%


TTEST 

Control vs Stable&Unstable 
Control vs Stable 
Control vs Unstable 



Table 9. Clinical characteristics of Cohort 2 

MI this 
LBBB RBBB LAD PVC MI ruled in admission Preinfarctional Killip class 

EKGLBBB EKGRBBB EKGLAD EKGPVC HPENCCAT MIORNOT MITHISAD PREINFAR KILLIP 

Average ( SD) 
Control #DIV/0! #DIV/0! #DIV/0! #DIV/0! 440 10 #DIV/0! 0.070.25 00 
Stable #DIV/0! #DIV/0! #DIV/0! #DIV/0! 43.324.67 10 #DIV/0! 00 00 
Unstable #DIV/0! #DIV/0! #DIV/0! #DIV/0! 40.389.88 1.290.46 #DIV/0! 0.110.31 00 
"Unstable" but no CAD #DIV/0! #DIV/0! #DIV/0! #DIV/0! 42.137.5 1.090.3 #DIV/0! 0.130.34 00 
Unstable mild CAD #DIV/0! #DIV/0! #DIV/0! #DIV/0! 42.738.04 1.050.21 #DIV/0! 0.30.47 0.030.17 
Stable mild CAD #DIV/0! #DIV/0! #DIV/0! #DIV/0! 440 10 #DIV/0! 00 00 

Range ( SD) 
Control 44  44 1  1 0  1 0  0 
Stable 12  44 1  1 0  0 0  0 
Unstable 13  56 1  2 0  1 0  0 

"Unstable" but no CAD 14  44 1  2 0  1 0  0 
Unstable mild CAD 14  62 1  2 0  1 0  1 
Stable mild CAD 44  44 1  1 0  0 0  0 

Median 

Control 44 1 0 0 
Stable 441 0 0 
Unstable 44 1 0 0 

"Unstable" but no CAD 44 1 0 0 
Unstable mild CAD 44 1 0 0 
Stable mild CAD 44 1 0 0 

# (%)of entries numeric 
Control 0 (0%) 0 (0%) 0 (0%) 0 (0%) 47 (100%) 9 (19%) 0 (0%) 46 (98%) 47 (100%) 
Stable 0 (0%) 0 (0%) 0 (0%) 0 (0%) 47 (100%) 7 (15%) 0 (0%) 46 (98%) 47 (100%) 
Unstable 0 (0%) 0 (0%) 0 (0%) 0 (0%) 74 (100%) 42 (57%) 0 (0%) 74 (100%) 74 (100%) 
"Unstable" but no CAD 0 (0%) 0 (0%) 0 (0%) 0 (0%) 16 (100%) 11 (69%) 0 (0%) 16 (100%) 16 (100%) 
Unstable mild CAD 0 (0%) 0 (0%) 0 (0%) 0 (0%) 33 (100%) 22 (67%) 0 (0%) 33 (100%) 33 (100%) 
Stable mild CAD 0 (0%) 0 (0%) 0 (0%) 0 (0%) 35 (100%) 3 (9%) 0 (0%) 34 (97%) 35 (100%) 

TTEST ** 
Control vs Stable&Unstable 0.001426214 
Control vs Stable 0.32254205 
Control vs Unstable 0.002336657 


Table 9. Clinical characteristics of Cohort 2 

Number of 
significantly 
Family hx of Body surface Diastolic blood Systolic blood obstructed 
CAD area pressure pressure Unstable vessels 


** 

FHX_PRED BSA BMI DIASBP SYSBP PULSE UNSTABLE NUMDZV CGSEQ 

Average ( SD) 

Control 0.260.44 1.980.25 31.738.6 84.7813.42 144.4324.76 81.7942.14 00 00 10 
Stable 0.450.5 1.970.21 29.125.02 85.9313.06 155.5921.59 74.0617.12 00 1.470.95 10 
Unstable 0.530.5 2.020.24 30.346.65 84.7914.86 149.1325.59 67.1114.24 10 1.760.79 10 

"Unstable" but no CAD 0.630.5 2.040.23 35.889.78 85.8814.03 140.8817.59 67.2513.11 10 00 10 
Unstable mild CAD 0.450.51 2.030.27 29.375.18 79.0613.27 134.2521.38 65.1814.71 10 00 10 
Stable mild CAD 0.510.51 2.080.23 31.847.04 85.7514.13 149.8421.24 75.2928.65 00 00 10 

Range ( SD) 

Control 0  1 1.6  2.58 20.2  53.96 63  121 110  208 42  288 0  0 0  0 1  1 
Stable 0  1 1.63  2.47 15.08  45.06 58  115 122  203 44  125 0  0 0  3 1  1 
Unstable 0  1 1.51  2.51 17.99  52.07 60  126 99  223 42  115 1  1 0  3 1  1 

"Unstable" but no CAD 0  1 1.57  2.4 15.83  52.07 60  110 108  167 42  95 1  1 0  0 1  1 
Unstable mild CAD 0  1 1.58  2.64 20.7  45.33 52  108 100  192 38  94 1  1 0  0 1  1 
Stable mild CAD 0  1 1.6  2.57 19.38  51.19 57  116 115  208 46  216 0  0 0  0 1  1 

Median 

Control0 2 29 8013873 0 0 1 
Stable0 2 29 8715370 0 1 1 
Unstable1 2 29 85 145 66 1 2 1 

"Unstable" but no CAD 1 2 36 90 145 66 1 0 1 
Unstable mild CAD 0 2 29 79 133 63 1 0 1 
Stable mild CAD 1 2 30 88 150 70 0 0 1 

# (%)of entries numeric 
Control 47 (100%) 47 (100%) 47 (100%) 46 (98%) 46 (98%) 47 (100%) 36 (77%) 43 (91%) 47 (100%) 
Stable 47 (100%) 45 (96%) 45 (96%) 44 (94%) 44 (94%) 47 (100%) 27 (57%) 47 (100%) 47 (100%) 
Unstable 74 (100%) 74 (100%) 74 (100%) 67 (91%) 67 (91%) 74 (100%) 74 (100%) 74 (100%) 74 (100%) 
"Unstable" but no CAD 16 (100%) 15 (94%) 15 (94%) 16 (100%) 16 (100%) 16 (100%) 16 (100%) 16 (100%) 16 (100%) 
Unstable mild CAD 33 (100%) 33 (100%) 33 (100%) 32 (97%) 32 (97%) 33 (100%) 33 (100%) 33 (100%) 33 (100%) 
Stable mild CAD 35 (100%) 35 (100%) 35 (100%) 32 (91%) 32 (91%) 35 (100%) 27 (77%) 35 (100%) 35 (100%) 

TTEST -** 
Control vs Stable&Unstable 0.181630067 0.847647063 0.09611889 0.063370156 
Control vs Stable 0.077354899 0.681634156 0.024964623 0.248914231 
Control vs Unstable 0.348220678 0.997499831 0.33058619 0.02507789 


Table 9. Clinical characteristics of Cohort 2 

LDLDT LDL HDLDT HDL TRIGLYDT TRIGLY TCHOLDT TOTCHOL GLUCOSDT 

Average ( SD) 

Control #DIV/0! 87.6732.22 #DIV/0! 46.2510.64 #DIV/0! 161.9277.08 #DIV/0! 166.4234.12 #DIV/0! 
Stable #DIV/0! 104.0830.52 #DIV/0! 45.8514.14 #DIV/0! 205.69124.86 #DIV/0! 186.5735.63 #DIV/0! 
Unstable #DIV/0! 88.4742.2 #DIV/0! 44.9716.75 #DIV/0! 210.32157.22 #DIV/0! 173.8643.03 #DIV/0! 
"Unstable" but no CAD #DIV/0! 101.8934.48 #DIV/0! 5015.03 #DIV/0! 178.22104.01 #DIV/0! 187.5622.05 #DIV/0! 
Unstable mild CAD #DIV/0! 89.7634.09 #DIV/0! 48.2421.07 #DIV/0! 159.9463.68 #DIV/0! 170.0631.59 #DIV/0! 
Stable mild CAD #DIV/0! 108.9229.49 #DIV/0! 50.3313.51 #DIV/0! 181.6787.56 #DIV/0! 194.2338.64 #DIV/0! 


Range ( SD) 

Control 30  145 34  73 55  304 119  218 
Stable 60  164 31  70 41  459 136  255 
Unstable 23  181 12  98 50  778 102  257 

"Unstable" but no CAD 77  184 35  79 51  365 159  232 
Unstable mild CAD 1  142 29  117 75  298 110  230 
Stable mild CAD 57  147 39  88 74  412 134  274 

Median 

Control 79 45 142 173 
Stable 101 42 198 183 
Unstable 87 41 160 172 

"Unstable" but no CAD 89 46 192 178 
Unstable mild CAD 96 40 144 163 
Stable mild CAD 114 45 158 201 

# (%)of entries numeric 

Control 0 (0%) 12 (26%) 0 (0%) 12 (26%) 0 (0%) 12 (26%) 0 (0%) 12 (26%) 0 (0%
Stable 0 (0%) 12 (26%) 0 (0%) 13 (28%) 0 (0%) 13 (28%) 0 (0%) 14 (30%) 0 (0%
Unstable 0 (0%) 34 (46%) 0 (0%) 37 (50%) 0 (0%) 37 (50%) 0 (0%) 37 (50%) 0 (0%
"Unstable" but no CAD 0 (0%) 9 (56%) 0 (0%) 9 (56%) 0 (0%) 9 (56%) 0 (0%) 9 (56%) 0 (0%
Unstable mild CAD 0 (0%) 17 (52%) 0 (0%) 17 (52%) 0 (0%) 17 (52%) 0 (0%) 17 (52%) 0 (0%
Stable mild CAD 0 (0%) 12 (34%) 0 (0%) 12 (34%) 0 (0%) 12 (34%) 0 (0%) 13 (37%) 0 (0%


TTEST 

Control vs Stable&Unstable 0.661994769 0.78540401 0.132055022 0.349806708 
Control vs Stable 0.213411775 0.936126072 0.300108225 0.154441568 
Control vs Unstable 0.946154051 0.75910906 0.163736817 0.545013463 



Table 9. Clinical characteristics of Cohort 2 

GLUCOSE CREATDT CREATIN HXICC HXCABG TRANSPLT LMAIN LOSTIUM LMCNORM 

Average ( SD) 
Control 115.5740.03 #DIV/0! 1.071.24 00 00 00 0.060.25 00 10 
Stable 123.1843.28 #DIV/0! 1.391.7 00 00 00 0.320.63 0.170.38 1.360.67 
Unstable 120.0346.98 #DIV/0! 1.070.34 0.310.47 00 00 0.360.54 0.250.46 1.540.74 
"Unstable" but no CAD 118.1341.63 #DIV/0! 0.990.24 00 00 00 00 00 10 
Unstable mild CAD 119.9451.84 #DIV/0! 1.020.24 0.090.29 00 00 0.090.3 0.030.18 1.240.9 
Stable mild CAD 118.9355.86 #DIV/0! 1.030.22 00 00 00 0.260.44 0.140.43 1.170.38 

Range ( SD) 
Control 69  235 0.6  9.2 0  0 0  0 0  0 0  1 0  0 1  1 
Stable 55  272 0.6  12.2 0  0 0  0 0  0 0  3 0  1 1  3 
Unstable 72  343 0.4  2.7 0  1 0  0 0  0 0  2 0  2 1  5 

"Unstable" but no CAD 85  233 0.6  1.5 0  0 0  0 0  0 0  0 0  0 1  1 
Unstable mild CAD 75  285 0.7  1.6 0  1 0  0 0  0 0  1 0  1 1  6 
Stable mild CAD 60  328 0.6  1.6 0  0 0  0 0  0 0  1 0  2 1  2 

Median 

Control101 1000001 
Stable111 1000001 
Unstable107 1000001 

"Unstable" but no CAD 101 1 0 0 0 0 0 1 
Unstable mild CAD 105 1 0 0 0 0 0 1 
Stable mild CAD 99 1 0 0 0 0 0 1 

# (%)of entries numeric 

Control 46 (98%) 0 (0%) 46 (98%) 47 (100%) 47 (100%) 47 (100%) 47 (100%) 47 (100%) 47 (100%
Stable 45 (96%) 0 (0%) 47 (100%) 47 (100%) 47 (100%) 47 (100%) 47 (100%) 47 (100%) 47 (100%
Unstable 71 (96%) 0 (0%) 74 (100%) 74 (100%) 74 (100%) 74 (100%) 73 (99%) 73 (99%) 74 (100%
"Unstable" but no CAD 16 (100%) 0 (0%) 16 (100%) 16 (100%) 16 (100%) 16 (100%) 16 (100%) 16 (100%) 16 (100%
Unstable mild CAD 31 (94%) 0 (0%) 33 (100%) 33 (100%) 33 (100%) 33 (100%) 32 (97%) 32 (97%) 33 (100%
Stable mild CAD 30 (86%) 0 (0%) 35 (100%) 35 (100%) 35 (100%) 35 (100%) 35 (100%) 35 (100%) 35 (100%


TTEST *** 

Control vs Stable&Unstable 0.435175579 0.550808653 5.70582E-11 
Control vs Stable 0.386331593 0.296033325 0.000604477 
Control vs Unstable 0.58367095 0.991504486 2.45162E-08 


Table 9. Clinical characteristics of Cohort 2 

LMST LOSTST PROBLEM COMMENTS CATHAGE AOOMED AOODX ACS DISCREPANCY 

Average ( SD) 

Control 0.321.24 00 #DIV/0! #DIV/0! 53.0410.88 #DIV/0! #DIV/0! #DIV/0! #DIV/0! 
Stable 8.318.77 7.1319.94 #DIV/0! #DIV/0! 65.39.86 66.256.7 #DIV/0! #DIV/0! #DIV/0! 
Unstable 11.7820.38 7.0516.22 #DIV/0! #DIV/0! 63.4210.02 70.411.26 #DIV/0! #DIV/0! #DIV/0! 
"Unstable" but no CAD 00 00 #DIV/0! #DIV/0! 50.511.52 #DIV/0! #DIV/0! #DIV/0! #DIV/0! 
Unstable mild CAD 3.1310.53 0.160.88 #DIV/0! #DIV/0! 57.7311.8 #DIV/0! #DIV/0! #DIV/0! #DIV/0! 
Stable mild CAD 4.2910.65 2.297.11 #DIV/0! #DIV/0! 58.718.32 #DIV/0! #DIV/0! #DIV/0! #DIV/0! 


Range ( SD) 

Control 0  5 0  0 30  73 
Stable 0  75 0  75 45  89 60  73 
Unstable 0  75 0  75 40  85 52  82 


"Unstable" but no CAD 0  0 0  0 28  74 
Unstable mild CAD 0  50 0  5 37  83 
Stable mild CAD 0  50 0  25 46  78 

Median 

Control 0 0 55 
Stable 0 0 63 66 
Unstable 0 0 63 72 

"Unstable" but no CAD 0 0 48 
Unstable mild CAD 0 0 56 
Stable mild CAD 0 0 57 

# (%)of entries numeric 
Control 47 (100%) 47 (100%) 0 (0%) 0 (0%) 47 (100%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 
Stable 47 (100%) 47 (100%) 0 (0%) 0 (0%) 47 (100%) 4 (9%) 0 (0%) 0 (0%) 0 (0%) 
Unstable 73 (99%) 73 (99%) 0 (0%) 0 (0%) 74 (100%) 5 (7%) 0 (0%) 0 (0%) 0 (0%) 
"Unstable" but no CAD 16 (100%) 16 (100%) 0 (0%) 0 (0%) 16 (100%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 
Unstable mild CAD 32 (97%) 32 (97%) 0 (0%) 0 (0%) 33 (100%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 
Stable mild CAD 35 (100%) 35 (100%) 0 (0%) 0 (0%) 35 (100%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 

TTEST *** *** *** 
Control vs Stable&Unstable 1.56376E-07 2.49965E-05 4.24892E-08 
Control vs Stable 0.00557595 0.018116835 1.33246E-07 
Control vs Unstable 8.53266E-06 0.00039665 8.923E-07 


Table 9. Clinical characteristics of Cohort 2 

Days until 
death 

NEWAFFSTAT AMGLUC AMGLUCDATE HGA1C HGA1CDATE PROBNP PROBNPDATE CAUSE DDEATH 

Average ( SD) 
Control #DIV/0! #DIV/0! #DIV/0! #DIV/0! #DIV/0! #DIV/0! #DIV/0! #DIV/0! 4.6221.47 
Stable #DIV/0! #DIV/0! #DIV/0! #DIV/0! #DIV/0! #DIV/0! #DIV/0! 160 94.4106.5 
Unstable #DIV/0! #DIV/0! #DIV/0! #DIV/0! #DIV/0! #DIV/0! #DIV/0! 160 166.7490.97 
"Unstable" but no CAD #DIV/0! #DIV/0! #DIV/0! #DIV/0! #DIV/0! #DIV/0! #DIV/0! #DIV/0! 00 
Unstable mild CAD #DIV/0! #DIV/0! #DIV/0! #DIV/0! #DIV/0! #DIV/0! #DIV/0! #DIV/0! 25.8264.68 
Stable mild CAD #DIV/0! #DIV/0! #DIV/0! #DIV/0! #DIV/0! #DIV/0! #DIV/0! #DIV/0! 13.3152.33 

Range ( SD) 
Control 0  113 
Stable 16  16 0  262 
Unstable 16  16 0  289 

"Unstable" but no CAD 0  0 
Unstable mild CAD 0  233 
Stable mild CAD 0  292 

Median 

Control 0 
Stable 17 
Unstable 16 197 

"Unstable" but no CAD 0 
Unstable mild CAD 0 
Stable mild CAD 0 

# (%)of entries numeric 

Control 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 47 (100%
Stable 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 1 (2%) 47 (100%
Unstable 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 2 (3%) 74 (100%
"Unstable" but no CAD 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 16 (100%
Unstable mild CAD 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 33 (100%
Stable mild CAD 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 35 (100%


TTEST *** 

Control vs Stable&Unstable 1.74218E-27 
Control vs Stable 7.31314E-07 
Control vs Unstable 4.19376E-25 


Table 9. Clinical characteristics of Cohort 2 

Days to 
Days to Days to Days to Days to Days to subsequent Days to 
subsequent subsequent subsequent subsequent subsequent Duke ICC Days to subsequent 
Death CABG Duke CABG cath Duke cath ICC procedure procedure subsequent MI PTCA 

DEATH DSCABG DSCABGD DSCATH DSCATHD DSICC DSICCD DSMI DSPTCA 

Average ( SD) 

Control 00 #DIV/0! #DIV/0! 970 970 #DIV/0! #DIV/0! 1130 #DIV/0! 
Stable 0.020.15 4.135.79 4.135.79 3.339.05 3.339.05 0.823.62 0.823.62 #DIV/0! 0.823.62 
Unstable 0.030.16 10.532.43 10.532.43 14.7352.94 14.7352.94 0.130.66 0.130.66 80.3364.81 0.130.66 

"Unstable" but no CAD 00 #DIV/0! #DIV/0! #DIV/0! #DIV/0! #DIV/0! #DIV/0! #DIV/0! #DIV/0! 
Unstable mild CAD 00 #DIV/0! #DIV/0! 14.6725.4 14.6725.4 00 00 #DIV/0! 00 
Stable mild CAD 00 600 600 00 00 #DIV/0! #DIV/0! #DIV/0! #DIV/0! 

Range ( SD) 

Control 0  0 97  97 97  97 113  113 
Stable 0  1 1  18 1  18 0  32 0  32 0  17 0  17 0  17 
Unstable 0  1 1  132 1  132 0  289 0  289 0  4 0  4 6  125 0  4 

"Unstable" but no CAD 0  0 
Unstable mild CAD 0  0 0  44 0  44 0  0 0  0 0  0 
Stable mild CAD 0  0 60  60 60  60 0  0 0  0 

Median 

Control 0 
Stable0220000 0 
Unstable0 2 2 0 0 0 0110 0 

"Unstable" but no CAD 0 
Unstable mild CAD 0 0 0 
Stable mild CAD 0 

# (%)of entries numeric 

Control 47 (100%) 0 (0%) 0 (0%) 1 (2%) 1 (2%) 0 (0%) 0 (0%) 1 (2%) 0 (0%) 
Stable 47 (100%) 8 (17%) 8 (17%) 15 (32%) 15 (32%) 22 (47%) 22 (47%) 0 (0%) 22 (47%) 
Unstable 74 (100%) 16 (22%) 16 (22%) 40 (54%) 40 (54%) 39 (53%) 39 (53%) 3 (4%) 39 (53%) 
"Unstable" but no CAD 16 (100%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 
Unstable mild CAD 33 (100%) 0 (0%) 0 (0%) 3 (9%) 3 (9%) 1 (3%) 1 (3%) 0 (0%) 1 (3%) 
Stable mild CAD 35 (100%) 1 (3%) 1 (3%) 1 (3%) 1 (3%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 

TTEST 

Control vs Stable&Unstable #DIV/0! #DIV/0! 
Control vs Stable #DIV/0! #DIV/0! 
Control vs Unstable #DIV/0! #DIV/0! #NUM! 



Table 9. Clinical characteristics of Cohort 2 

Days to 
Days to subsequent 
subsequent thrombolytic 
Duke PTCA therapy 


DSPTCAD DSTHROM One >70 two >50 criterea met? Any >9% # >90 # 70-90 # 50-70 
Average ( SD) 

Control #DIV/0! #DIV/0! 00 00 00 00 00 00 00 
Stable 0.823.62 #DIV/0! 1.71.1 2.490.98 10 3.491 0.910.83 0.790.93 0.790.98 
Unstable 0.130.66 #DIV/0! 1.931.1 2.71.19 10 3.651.1 1.341.05 0.590.68 0.770.79 
"Unstable" but no CAD #DIV/0! #DIV/0! 00 00 00 00 00 00 00 
Unstable mild CAD 00 #DIV/0! 00 0.270.45 00 1.821.13 00 00 0.270.45 
Stable mild CAD #DIV/0! #DIV/0! 00 0.310.47 00 2.031.12 00 00 0.310.47 

Range ( SD) 

Control 0  0 0  0 0  0 0  0 0  0 0  0 0  0 
Stable 0  17 0  4 1  4 1  1 1  5 0  3 0  3 0  3 
Unstable 0  4 0  5 1  5 1  1 1  5 0  4 0  2 0  3 

"Unstable" but no CAD 0  0 0  0 0  0 0  0 0  0 0  0 0  0 
Unstable mild CAD 0  0 0  0 0  1 0  0 1  5 0  0 0  0 0  1 
Stable mild CAD 0  0 0  1 0  0 1  5 0  0 0  0 0  1 

Median 

Control 0000000 
Stable0 2214110 
Unstable0 2314101 

"Unstable" but no CAD 0 0 0 0 0 0 0 
Unstable mild CAD 0 0 0 1 0 0 0 
Stable mild CAD 0 0 0 2 0 0 0 

# (%)of entries numeric 

Control 0 (0%) 0 (0%) 47 (100%) 47 (100%) 47 (100%) 47 (100%) 47 (100%) 47 (100%) 47 (100%
Stable 22 (47%) 0 (0%) 47 (100%) 47 (100%) 47 (100%) 47 (100%) 47 (100%) 47 (100%) 47 (100%
Unstable 39 (53%) 0 (0%) 74 (100%) 74 (100%) 74 (100%) 74 (100%) 74 (100%) 74 (100%) 74 (100%
"Unstable" but no CAD 0 (0%) 0 (0%) 16 (100%) 16 (100%) 16 (100%) 16 (100%) 16 (100%) 16 (100%) 16 (100%
Unstable mild CAD 1 (3%) 0 (0%) 33 (100%) 33 (100%) 33 (100%) 33 (100%) 33 (100%) 33 (100%) 33 (100%
Stable mild CAD 0 (0%) 0 (0%) 35 (100%) 35 (100%) 35 (100%) 35 (100%) 35 (100%) 35 (100%) 35 (100%


TTEST *** *** *** *** 

Control vs Stable&Unstable 1.09399E-36 5.69293E-51 1.14965E-67 8.82701E-25 
Control vs Stable 6.32649E-14 5.78746E-22 1.20027E-27 1.32457E-09 
Control vs Unstable 3.94582E-24 1.04833E-30 3.04801E-41 4.51691E-17 



Table 9. Clinical characteristics of Cohort 2 

# 25-50 # 10-25 # 1-10 # 0 Average %stenosis 
Average ( SD) 

Control 00 00 0.551.02 4.451.02 0.561.02 
Stable 0.980.87 0.020.15 0.280.58 1.230.84 42.6314.69 
Unstable 0.880.92 0.070.25 0.270.56 1.070.97 47.418.22 

"Unstable" but no CAD 00 00 0.310.7 4.690.7 0.310.7 
Unstable mild CAD 1.551.06 00 0.550.75 2.611.14 11.096.62 
Stable mild CAD 1.691.08 0.030.17 0.770.91 2.21.23 12.436.81 

Range ( SD) 

Control 0  0 0  0 0  4 1  5 0  4 
Stable 0  3 0  1 0  2 0  3 16  70 
Unstable 0  4 0  1 0  2 0  4 17  95 

"Unstable" but no CAD 0  0 0  0 0  2 3  5 0  2 
Unstable mild CAD 0  4 0  0 0  2 0  4 5  30 
Stable mild CAD 0  4 0  1 0  3 0  4 2.6  30 

Median 

Control0 0 0 5 0 
Stable1 0 0 1 44 
Unstable1 0 0 1 47 

"Unstable" but no CAD 0 0 0 5 0 
Unstable mild CAD 1 0 0 2 10 
Stable mild CAD 2 0 1 2 11 

# (%)of entries numeric 

Control 47 (100%) 47 (100%) 47 (100%) 47 (100%) 47 (100%
) 
Stable 47 (100%) 47 (100%) 47 (100%) 47 (100%) 47 (100%
) 
Unstable 74 (100%) 74 (100%) 74 (100%) 74 (100%) 74 (100%
) 
"Unstable" but no CAD 16 (100%) 16 (100%) 16 (100%) 16 (100%) 16 (100%
) 
Unstable mild CAD 33 (100%) 33 (100%) 33 (100%) 33 (100%) 33 (100%
) 
Stable mild CAD 35 (100%) 35 (100%) 35 (100%) 35 (100%) 35 (100%
) 


TTEST *** -*** *** 

Control vs Stable&Unstable 2.11498E-20 0.079284732 1.92771E-31 1.69586E-56 
Control vs Stable 8.36916E-10 0.109536115 3.90584E-29 4.35507E-24 
Control vs Unstable 5.79194E-12 0.085344001 1.54246E-32 3.38252E-34 


Table 10. Disease Classifications of Cohort 2 Samples 


N Classification Stenosis 
41 Control No stenosis 
18 Mild All  25 (or  50 in small vessel) 
67 Intermediate Worst = 50 (or  50 in small vessel 
86 Significant At least one vessel 70% 
29 MVD  3 lesions (70%LM=2; 50%LM=1) 


Table 12. Groups of covarying genes that are predictive of CAD 


Set Group A Group B Group C Group D Group E 
Genes S100A12 XK TUBB2 IFNG CSF3R 
S100A8 P62 PDGFB TLR5 
S100A9 FECH VSIG4 CD46 
BCL2A1 TNF NCF1 
F5 
Set Correlation 0.78 0.82 1 0.45 0.70 


Table 19. Genes identified in feasibility study for metagene models of Example 12 


Gene Symbol Gene Symbol Gene Symbol Gene Symbol 
18S CLK3 LOXL2 RPL8 
ADORA3* COL6A2 LPGAT1 RPS27A 
ADRB2 COTL1 MAP4K1 RPS4Y1 
AF161365 CR609588 MAPK8IP1 RRN3 
AL137734 CSF2RA MARCO RSU1 
ALAS2 CSF3R MBOAT2 RXRA 
ARF1 CSTA* MCOLN2 S100A12* 
ARG1* CXCL1 MFN2 S100A9* 
ARL17P1 DAPK1 MMD SEMA7A 
ASGR2 DB097529 MPZL1 SERGEF 
ASMTL DERL3* MUTYH SERPINB2 
ATP11B DHFR NDFIP1 SET 
ATP1B1 DPM3 NDST1 SIT1 
ATP8B4 EPOR NDUFS7 SLAMF1 
BBS5 EXOC3 NR1D1 SLC22A1 
BC032451* FAM13A1 OLIG1* SLC29A1* 
BC089454 FBXO2 OLIG2* SLK 
BCL2A1* FCGBP PAPSS1 SMN1 
BCL9L FOLR3 PDGFB SNAPAP 
BQ130147 FOXK1 PDS5A SPOP 
BU540282 FRAT1 PF4 SPSB2 
C11orf2 FVT1 POLR2L SSU72 
C12orf65 GALNT14 PPP2CB ST3GAL1 
C20orf11 GPR114 PRDX6 ST6GALNAC3 
CACNA2D2 GSTO1 PRIM1 TARP 
CARKL GSTP1 PRO1853 TCF7 
CASP9 GZMK RAB11FIP1 TLR5 
CAT HDC RAN TMEM176B 
CB853344 HGF RCAN3 TNF 
CBS* HSPB1 REEP3 TNFSF10 
CCL23 IFNG REEP5 TPI1 
CCR1 IGHA1* RELA TRA 
CCR5 IGHA2 RGS1 TUBB2 
CD248 IL10 RGS18 TUBB2A 
CD320 IL18 RHOH TXN* 
CD33 IRF2 RIC8A U2AF1L4 
CD3E JAK2 RNASE2 UBA52 
CD70 KLF4 RPL10A VEGFB 
CDC42SE2 KLRG1 RPL28 VSIG4 
CEP68 LGALS1 RPL28.1 XK 
CKLF LIF RPL28.2 YWHAZ 
CLC* LOC644246 RPL34 ZNF786 


Table 20. Clinical demographics of 180 samples used for validation of metagene 
models experiment 

N = 180 
Sex 57% Male 
43% Female 
Race 72% Caucasian 
18% Black 
10% Other/Missing 
Age Median = 60yrs 
Range = 23 to 83 
Hx Smoking 29% Yes 
71% No 
Presentation 82% Stable 
18% Unstable 
Hx Hyperlipidemia 41% Yes 
59% No 
Hx Hypertension 57% Yes 
43% No 
Family Hx CAD 26% Yes 
74% No 
CAD Group 20% Group 1a 
7% Group 2a 
28% Group 3b 
35 % Group 4c 
9% Group 5c 

a Control, b Intermediate, c Case 


Table 21. Number of samples missing data for each gene in validation of metagene 
models experiment 

Term Gene 
Name 
Number 
Missing 
Metagene I S100A12 0 
S100A9 0 
BLC2A1 0 
TXN 0 
CSTA 0 
Metagene II OLIG1 0 
OLIG2 3* 
ADORA3 0 
CLC 0 
SLC29A1 0 
Metagene 
III 
DERL3 0 
IGHA1 0 
BC032451 0 
Metagene 
IV 
CBS 1** 
ARG1 0 
Norm RPL28 0 

* ID 5916, 6008, 6161 
** ID 4763 

Table 22. Summary statistics for validation of metagene models experiment. 


Term Gene Name Control Mean 
(SE) 
Intermediate 
Mean (SE) 
Case Mean (SE) 
Algorithm 1 14.46 (0.12) 14.27 (0.11) 18.82 (0.10) 
Algorithm 2 21.74 (0.14) 21.70 (0.13) 22.24 (0.11) 
Metagene I 5.81 (0.11) 5.90 (0.10) 5.47 (0.09) 
Metagene II 8.78 (0.13) 8.72 (0.13) 8.40 (0.08) 
Metagene III 8.58 (0.15) 8.79 (0.13) 8.73 (0.11) 
Metagene IV 10.65 (0.17) 11.04 (0.15) 10.24 (0.15) 
Metagene I S100Al2 5.19 (0.14) 5.32 (0.15) 4.79 (0.12) 
S100A9 8.92 (0.10) 9.11 (0.09) 8.69 (0.09) 
BLC2A1 0.86 (0.13) 1.06 (0.12) 0.44 (0.09) 
TXN 6.24 (0.10) 6.29 (0.09) 5.94 (0.09) 
CSTA 7.89 (0.13) 7.82 (0.12) 7.53 (0.11) 
Metagene II OLIG1 7.79 (0.12) 7.97 (0.12) 7.63 (0.06) 
OLIG2 11.16 (0.19) 11.01 (0.18) 10.72 (0.12) 
ADORA3 10.80 (0.14) 10.71 (0.12) 10.29 (0.11) 
CLC 6.44 (0.16) 6.25 (0.17) 5.92 (0.10) 
SLC29A1 7.72 (0.12) 7.63 (0.11) 7.42 (0.08) 
Metagene III DERL3 8.97 (0.09) 9.20 (0.09) 9.12 (0.07) 
BCO32451 10.35 (0.21 10.52 (0.16) 10.47 (0.15) 
IGHA1 6.43 (0.18) 6.64 (0.18) 6.60 (0.14) 
Metagene IV CBS 10.79 (0.20) 11.29 (0.20) 10.60 (0.17) 
ARG1 10.51 (0.20) 10.79 (0.18) 9.87 (0.19) 
Norm RPL28 21.33 (0.06) 21.26 (0.07) 21.43 (0.06) 


Table 23. Primary and secondary ANOVA comparisons for validation of metagene 
models experiment. 

Term Gene Name ANOVA 
p 
Int. v 
Control p2 
Case v 
Control 
p2 
Case v 
Int. p2 
ANOVA p 
(corrected)1 
Algorithm 1 *0.0087 0.8417 0.0462 0.0074 *0.0019 
Algorithm 2 *0.0021 0.9744 0.0122 0.0052 *3.00E-04 
Metagene I 0.0087 0.8417 0.0462 0.0074 0.0019 
Metagene II 0.0059 0.9081 0.0242 0.0724 0.0012 
Metagene III 0.4629 0.5544 0.6831 0.9469 0.3771 
Metagene IV 0.0305 0.2501 0.163 0.0011 0.01 
Algorithm 2a (Metagene I / 
Metagene II) .0019 .9465 .0116 .0035 .0003 
Algorithm 2b (Metagene I / 
Metagene IV) .0066 .6494 .0400 .0019 .0013 
Algorithm 2c (Metagene II / 
Metagene IV) .0020 .8334 .0133 .0015 .0003 
Algorithm 2d (Metagene I / 
Metagene II / Metagene IV) .0018 .8008 .0122 .0011 .0002 
Metagene I S100A12 0.0201 0.8113 0.0931 0.0151 0.0057 
S100A9 0.0412 0.4002 0.192 0.0045 0.0148 
BLC2A1 0.0035 0.4694 0.0257 3.00E-04 6.00E-04 
TXN 0.0131 0.9227 0.0615 0.0189 0.0032 
CSTA 0.0236 0.9117 0.0789 0.1925 0.007 
Metagene II OLIG1 0.1301 0.4339 0.4294 0.0247 0.0703 
OLIG2 0.0358 0.7958 0.1036 0.3663 0.0127 
ADORA3 0.0018 0.8977 0.0086 0.0318 2.00E-04 
CLC 0.0053 0.6395 0.0186 0.1842 0.001 
SLC29A1 0.0295 0.8311 0.09 0.2968 0.0099 
Metagene III DERL3 0.2476 0.165 0.3723 0.7789 0.1656 
BC032451 0.6698 0.8171 0.8791 0.981 0.6076 
IGHA1 0.5076 0.6793 0.7419 0.9802 0.4248 
Metagene IV CBS 0.318 0.2047 0.7691 0.0267 0.2305 
ARG1 0.0096 0.6161 0.0557 0.0025 0.0021 
Norm RPL28 0.2203 0.8074 0.5456 0.1863 0.1407 

* Primary Analysis, p<.005 criteria for success. 
1 Linear model with the following terms in addition to disease category: sex (0/1), age 
(yrs), hypertension (0/1), smoking (0/1), family history of CAD (0/1) 
2 Tukey HSD multiple comparisons adjustment 

Table 24. Primary and secondary AUC comparisons for the validation of metagene 
models experiment. 

Algorithm 1 Algorithm 2 2a 2b 2c 2d 
Intermediates Grouped With Controls 
AUC .64 .65 .66 .65 .66 .66 
AUC standard 
error 
.04 .04 .04 .04 .04 .04 
AUC p (test vs 
0.5) 
*.0007 *.0002 <.0001 .0004 <.0001 <.0001 
AUC 95% CI .56 to .72 .57 to .73 .58 to .74 .57 to .73 .58 to .74 .58 to .74 
Retrospective 
Cutoff 
14.4 21.8 20.6 21.5 23.3 18.8 
Sensitivity 74% 74% 74% 75% 74% 73% 
Specificity 52% 52% 55% 47% 47% 50% 
Intermediates Grouped With Cases 
AUC .58 .59 
AUC standard 
error 
.05 .05 
AUC p (test vs 
0.5) 
*.070 *.053 
AUC 95% CI .49 to .68 .50 to .68 
Retrospective 
Cutoff 
14.3 21.7 
Sensitivity 68% 64% 
Specificity 51% 53% 
Intermediates Excluded 
AUC .64 .65 
AUC standard 
error 
.05 .05 
AUC p (test vs 
0.5) 
*.008 *.003 
AUC 95% CI .54 to .74 .55 to .75 
Retrospective 
Cutoff 
14.3 21.8 
Sensitivity 76% 74% 
Specificity 51% 53% 


